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Abstract 
Rhabdomyosarcoma is a family of rare juvenile cancers that express molecular factors 
implicated in myogenic differentiation. Cell cycle arrest is absolutely necessary for muscle 
maturation, while abnormal cell cycle and cell death programs are hallmarks of cancer onset and 
progression. The cancerous rhabdomyosarcoma cells continue to uncontrollably proliferate in 
part due to deficiencies in the myogenic program. Electrical stimulation is known to alter the 
phenotype of myogenic cells, such changes include cell cycle arrest and enhanced myoblast 
differentiation. Since rhabdomyosarcoma tumors are muscle-like this thesis looks at the use 
electrical stimulation towards these cells in an attempt to induce differentiation and prevent 
growth. The results indicate that the response elicited in rhabdomyosarcoma cells following 
electrical stimulation is different from the one observed in myoblasts, however cell cycle arrest 
and cell death through autophagy contribute to a large reduction in the number of cells, which 
represents a potential therapeutic approach. 
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Review of Literature 
1. Mammalian Cell Cycle 
During cell division the cell goes through a series of distinct and tightly regulated stages 
during which it replicates its DNA and then divides into two identical daughter cells (reviewed in 
(1)). Upon entering the cell cycle either following the completion of the previous round of 
division or from a quiescent state termed G0, cells enter into the gap 1 (G1) stage where they 
integrate all the extrinsic and intrinsic inputs and ready themselves for transition into S 
(synthesis) phase. Once in S phase, the cell initiates the replication of all chromosomal DNA. 
With two copies of the original DNA content the cell then enters the gap 2 (G2) phase where it 
ensures integrity of the genetic material and chromosomes, and prepares for Mitosis. G1, S and 
G2 together are referred to as interphase. M phase, or Mitosis, is the final step in the process. 
This is when the cell partitions the chromosomes and undergoes cytokinesis, dividing all cellular 
contents into two new identical daughter cells (1)(See Figure 1).  
Progression through the cell cycle is controlled by a family of proteins known as cyclin-
dependent kinases (CDKs) (reviewed in (2)). CDK activity is reliant on their interaction with a 
class of proteins referred to as cyclins. A number of cyclin/CDK complexes regulate the various 
stages of the cell cycle, each playing a specific role. CDK4/CDK6 complexes regulate the G1 
stage, while CDK2 and its cyclins are responsible for G1/S transition and S phase (2). CDK1 
activity is actuated throughout the G2 phase and regulates the initiation of Mitosis (2). CDK7 is 
thought to participate in the activation of the other cyclin/CDK complexes (2). Knock-out studies 
of the cyclins, and their corresponding CDKs, indicate that the remaining proteins are often able 
to compensate for the missing ones (3). Reports claim that in most cases CDK1 is sufficient for 
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the full completion of the cell cycle when all other interphase CDKs are absent (4). CDK1, as 
well as Cyclin A2 and B1, appear to be indispensable for the cell cycle process (4).  
Throughout the cell cycle CDK protein levels tend to remain relatively constant. Thus, 
the major forms for their regulation are protein-protein interaction and post-translational 
modifications (5). A number of mechanisms are responsible for the control of CDK activation. 
One of these is the binding of the cyclin proteins to the appropriate CDK. Cyclin protein levels 
oscillate throughout the cell cycle, and their interaction with the CDKs is required for the activity 
of the complex (5). The changes in the protein levels of the cyclins are dependent upon the 
balance between synthesis and ubiquitin mediated proteolysis (5). Cyclin D expression is 
Figure 1. The cell cycle consists of 4 stages: G1, S, G2, and M. The transitions from one stage to 
the other are regulated by the cyclin/CDK complexes. INK4 and CIP/KIP proteins inhibit the 
cyclin/CDK complexes to allow strict control of cell cycle progress. Modified from Donovan J, 
Slingerland J. Transforming growth factor-ß and breast cancer: Cell cycle arrest by transforming 
growth factor-ß and its disruption in cancer. Breast Cancer Res. 2000;2(2):116-24. 
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induced during G1 downstream of mitogenic signals. As cells near the G1/S transition cyclin E 
expression is activated by E2F transcription factors (3). Cyclin A is synthesized as cells are 
replicating their DNA material and it regulates the exit from S phase (3). In the G2 phase, Cyclin 
A is degraded while Cyclin B is synthesized, the latter is responsible for the transition into 
mitosis. Prior to anaphase the Cyclin B is degraded by the anaphase promoting complex (APC) 
which allows the daughter cells to split (2). Cyclin protein levels and activities of the CDK 
complexes are subjects to strict and time dependent oscillations, which are necessary to prevent 
an aberrant cell cycle. Excessive levels of cyclins and CDKs drive the oncogenic transformation 
observed in many cancers (6)(see Cancer section for further discussion).     
Additional mechanisms that regulate CDK activation include a group of proteins, which 
consists of two families known together as CKIs (cyclin-dependent kinase inhibitors), which 
prevent the catalytic activity of the cyclin/CDK complexes through direct binding. The INK4 
family of proteins inhibits specifically the CDK4/6 complexes, while the CIP/KIP proteins (p21, 
p27 and p57) inhibit most CDKs (5). Also, two phosphorylation sites also regulate the activity of 
the cyclin/CDK complexes. The kinase Wee1 phosphorylates the CDK protein near its amino 
terminus and this modification is inhibitory to the activity of the complex. The phosphatase Cdc25 
removes this phosphate group, thus promoting CDK activity (5). Another phosphorylation required 
for the optimal activity of a cyclin/CDK complex is mediated by CDK activating kinase (CAK), 
which consists of CDK7 bound to Cyclin H (5). Altogether, these four mechanisms allow for precise 
regulation of progression through the cell cycle.  
Cells integrate various internal and external cues in order to gauge their progress and 
readiness throughout the various stages of the cell cycle. Growth factors promote cell cycle 
entry, and when withdrawn lead to cell cycle arrest before the onset of S phase (1). Most of the 
cell cycle regulation during the G1 phase and G1/S transition converges on Rb interaction with 
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E2Fs (7). E2Fs, a family of transcription factors, control many of the genes responsible for the 
replication of cellular DNA (8). Those transcription factors are bound and inhibited by the 
retinoblastoma protein (Rb), as well as Rb related proteins p107 and p130 (9). The interphase 
CDK complexes phosphorylate Rb at multiple residues, alleviating its inhibitory actions towards 
E2Fs (2).  Once a cell begins the DNA replication process it is irreversibly committed to a round 
of replication and must complete the cell cycle to preserve its integrity. Errors in vital areas such 
as DNA replication and chromatin assembly among others will result in abrogation of the 
subsequent cell cycle steps, prompting damage repairs or cell death (10). 
 
1.1 G1/S Transition 
The G1 phase is driven by Cyclin D/CKD4/6 complexes, while G1/S transition is 
completed by Cyclin E/CDK2 (7)(See Figure 2). In somatic cells mitogenic signals are a major 
contributing factor to the increase in Cyclin D protein levels during the early G1 phase (7). 
Increased transcription and inhibition of the degradation process lead to accumulation of Cyclin 
D which then binds CDK4 (7). Active CDK4 phosphorylates Rb, prompting the release and 
disinhibition of the E2F transcription factors (7). E2Fs in turn promote the expression of Cyclin 
E and other proteins necessary for S phase progression (8). The newly synthesized Cyclin E 
binds CDK2 which then phosphorylates Rb, in a positive feedback manner enhancing its own 
expression (7). During this phase the cell must ensure all essential factors required for a 
successful round of division are in place, these include adequate supply of nutrients and 
readiness of the intrinsic machinery required for DNA replication. Failure to do so will 
compromise the survival of the dividing cell. In order to proceed into S phase the Cyclin 
E/CDK2 complexes must overcome an inhibitory threshold imposed by the CIP/KIP proteins, 
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p27 amongst those (11). p27 actions are counteracted by numerous mechanisms. CDK2 itself 
phosphorylates p27 on threonine 187 promoting its ubiquitination and subsequent degradation. 
Serine 10 phosphorylation also leads to nuclear export and its cytoplasmic degradation (11, 12). 
Threonine 157 phosphorylation causes cytosolic retention, while phosphorylation on tyrosine 88 
disrupts the ability of p27 to inhibit Cyclin E/CDK2 (11). Unlike Cyclin E/CDK2, p27 binding to 
Cyclin D/CDK4/6 positively regulates the activity of the complex (7). This interaction helps 
sequester the protein away from Cyclin E/CDK2 complexes, thus alleviating the inhibitory 
effects of p27 (7). If the mitogenic input is withdrawn Cyclin D expression is reduced and INK4 
activity is upregulated, Cyclin D/CDK4 complexes no longer titrate the CIP/KIP proteins and 
Figure 2. Regulation of the G1/S transition. Mitogenic signals increase protein levels of Cyclin D 
which then binds and activates CDK4. The Cyclin D/CDK4 complexes phosphorylate Rb to 
cause the release and disinhibition of the E2F transcription factors. The newly synthesized 
Cyclin E once bound to CDK2 causes further phosphorylation of Rb, thus in a positive feedback 
manner enhancing its own expression. Cyclin E/CDK2 complexes are inhibited by p27 which 
must be degraded or sequestered to allow S phase entry. Modified from Sherr CJ, Roberts JM. 
CDK inhibitors: Positive and negative regulators of G 1-phase progression. Genes Dev. 
1999;13(12):1501-12. 
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this in turn limits Cyclin E/CDK2 activation (7). Ultimately, once the cyclin/CDK complexes 
overcome the inhibition by the CKIs and hyper-phosphorylate Rb, the E2F factors are free to 
express their target genes and initiate DNA synthesis. Throughout S phase, the ubiquitin ligase 
FBW7 tags Cyclin E for degradation, while Cyclin A levels accumulate. Cyclin A binds to 
CDK2 and promotes S phase exit once all the genetic material is properly replicated (2). The 
timing and complexity of molecular mechanisms involved in the regulation of the transition from 
G1 into S accentuates the importance of this stage in the decision to commit to a round of 
division and the proper completion of the process. 
 
1.2 G2/M Transition 
As cells enter the G2 phase Cyclin A associates with CDK1. However, as cells near the 
G2/M transition Cyclin A is degraded and the newly synthesized Cyclin B binds with CDK1. 
When activated, the Cyclin B/CDK1 complex is reported to phosphorylate a large number of 
proteins that regulate various structural processes essential for mitosis (reviewed in (13)). These 
events include nuclear envelope breakdown, chromosome condensation, centrosome separation 
and spindle assembly (13). Additionally, Cyclin B/CDK1 complexes contribute to the activation 
of the ubiquitin ligase APC. In turn, APC signals for the degradation of the anaphase inhibitors 
securins as well as the cyclin proteins, a step required for the further progression through mitosis 
(13). In anaphase the sister-chromatids are held together by a protein complex known as cohesin. 
In order to allow the separation of the chromatids cohesin has to be cleaved by the protease 
separase. Securins inhibit separase and hence block further separation of the daughter cells, an 
effect alleviated once APC signals for the degradation of securins (13). Once the binding action 
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of cohesin is removed the sister-chromatids are pulled apart then the cell begins cytokinesis and 
eventually divides into daughter cells. 
 
1.3 Cell Cycle Checkpoints 
Maintaining the integrity of the genetic material during replication is crucial in 
preventing oncogenic transformation or ensuring the survival of a cell. A complex network of 
safeguard mechanisms termed checkpoints ensure orderly progression of the cell cycle, which 
includes successful completion of each stage prior to further progress as well as a response to 
DNA damage and an attempt to repair it (14). When activated by both extrinsic and intrinsic 
stimuli checkpoints can arrest the G1/S or G2/M transitions or prevent further progress during S 
or M phase (14). Extrinsic signals are primarily integrated in the G1 stage. Early work identified 
a point termed R (restriction) point in the cell cycle past which the division process seems to 
proceed independently of further outside influence. Once past R point the cells are committed to 
a round of replication. Conversely, when mitogens are withdrawn prior to the R point the cell 
will not initiate DNA synthesis (1). The cellular signalling cascades involved in the regulatory 
step ultimately converge on the opposing actions of Cyclin E and p27, which regulate the G1/S 
transition (7).  
Once into S phase the cells are committed to completing the cell cycle, and the intrinsic 
mechanisms are largely in place to prevent errors or damage and ensure the timely order of the 
stages. Possible culprits for checkpoint activation include DNA damage, replication fork 
disruptions and faulty chromatin assembly (15). Many stressors can damage the DNA helix, 
often culminating in either a double strand break (DSB) or exposed single stranded DNA 
(ssDNA) (15). The response to these events is initiated by two enzymes which once recruited to 
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the damaged site, initiate the signalling pathways that will ultimately attempt to repair the 
damage and delay further cell cycle progress. ATM (ataxia telangiectasia mutated) is shown to 
be active in the presence of DSB, while ATR (ATM and rad3 related) is recruited in the presence 
of ssDNA (15). ATM and ATR will in turn activate various mediators that participate in the 
repair process, also they will trigger a signalling sequence that involves CHK1 and CHK2 (15). 
CHK1 is reported to inhibit cdc25 activation and thus limit CDK activation, namely the Cyclin 
E/CDK2 and Cyclin B/CDK1 complexes during the G1/S and G2/M transitions respectively (15). 
CHK2 is an activator of p53, a transcription factor whose target gene products mediate DNA 
damage response including the CDK inhibitor p21 (15). p53 arrests growth and proliferation, 
contributes to DNA repair and induces cell death pathways in response to genomic damage (16). 
The activity of p53 is central in preventing oncogenic transformation, it is one of the most 
frequently mutated genes in cancers which allows those malignant cells to evade checkpoint 
mediated regulation (16, 17).    
During S phase the cells perform extensive DNA synthesis, where possible aberrations 
besides the aforementioned DNA damage can occur, including a stalled replication fork. Once 
again an ATM/ATR regulated response will help preserve the integrity of the stalled replication 
forks, the initiation or firing of new ones, and as discussed above repair any genomic damage, 
thus attempting to recover DNA replication all while delaying further cell cycle progression (15). 
While in mitosis, the spindle assembly checkpoint (SAC) will arrest compromised cells prior to 
anaphase. As the name implies SAC ensures correct spindle assembly which in turn mediates 
proper chromosome segregation (18). SAC pathway proteins form the mitotic checkpoint 
complex which binds and inhibits cdc20, an activator of the APC/C complex, thus preventing the 
degradation of Cyclin B and securin and the subsequent progression through mitosis (18). This 
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highly regulated network of checkpoints is essential for proper cell cycle completion and the 
maintenance of cell integrity, and when this network is compromised severe malignancies can 
arise (see Cancer section).  
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2. Programmed Cell Death Pathways 
Cell death pathways are a set of evolutionary conserved mechanisms implicated in a 
range of functions in multicellular organisms such as development, tissue patterning, and 
homeostasis by regulating the removal of unwanted cells (19). Cell death pathways were 
originally classified based on the apparent cellular morphological features, but research has 
elucidated the biochemical properties that characterize the underlying molecular events (19). 
When deregulated, cell death pathways help shape disorders such as developmental defects, 
degenerative disorders and cancer (19).  Apoptosis and autophagy are well-defined forms of 
programmed cell death which, unlike necrosis, are regulated via molecular signalling 
mechanisms influenced by both external and internal stimuli. In contrast necrosis is less ordered 
and occurs as a result of cellular edema and disruption of the plasma membrane (19).  Even 
though apoptosis and autophagy are distinct molecular processes there exists a well-documented 
cross talk between the two pathways to ultimately render the cell capable of adequately 
responding to multiple stressors (20). 
 
2.1 Apoptosis 
Apoptosis was first defined by DNA fragmentation, condensation of the nucleus and 
plasma membrane blebbing (21). These events were shown to be orchestrated by a family of 
proteases known as caspases which cleave many of the cell’s proteins (21). However, now it 
appears that a number of related but caspase independent pathways also contribute to this form 
of cell death (22, 23). Apoptosis is primarily induced via one of two pathways, an extrinsically 
triggered sequence and an intrinsic response actuated by the mitochondria (24, 25)(See Figure 3). 
The caspase proteins can be subdivided into two groups commonly referred to as response 
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initiators and effectors. They are synthesized as the procaspase form and possess little catalytic 
ability, cleavage of the inactive zymogen detaches the inhibitory pro domain and activates the 
enzymatic properties (25). Caspase-8 initiates the extrinsic apoptosis pathway. It is activated 
following ligand binding to death receptors which then induces the downstream apoptotic 
signalling (25). The intrinsic stimuli converge on mitochondrial outer membrane 
permeabilization (MOMP). Mitochondrial proteins cytochrome c and Apaf-1, once released into 
the cytoplasm, form a complex together with procaspase-9. This complex, often referred to as the 
apoptosome, helps cleave caspase-9 and initiate the execution of apoptosis (25). Both caspase-8 
and -9 are initiator caspases and once they are activated by the upstream stimuli they initiate the 
caspase cascade and cleave the apoptotic effectors. The effector caspases in turn are responsible 
for mediating the apoptotic events, this group includes caspase-3, -6 and -7. Among their targets 
are caspase activated DNases which fragment DNA, nuclear laminins and other cytoskeletal 
proteins (21). 
The mitochondrion is an organelle responsible for the majority of cellular ATP 
production in oxygen rich environments. Disruption of this mitochondrial function could lead to 
cell death independent of apoptotic signalling (26, 27). However, mitochondria are also central to 
the integration of intrinsic apoptotic stimuli (26, 27). MOMP and the consequent release of 
certain mitochondrial contents into the cytoplasm is considered a point of no return in 
programmed cell death. While many events have the capacity to contribute leading up to this 
stage, the opening of the mitochondrial permeability transition pore (mtPTP) is an event that will 
lead to organelle swelling, loss of membrane potential and eventually rupture of the outer 
membrane. mtPTP opening could be triggered by stimuli such as excessive amount of 
intracellular calcium or reactive oxygen species (ROS) (26, 27). The Bcl-2 family of proteins are 
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also crucial regulators of MOMP. These proteins are divided into two groups as either pro or 
anti-apoptotic. The Bax and Bak proteins oligomerize to form a pore in the outer mitochondrial 
membrane which would cause permeabilization (26, 27). This interaction is prevented via 
competitive binding with the anti-apoptotic members of the Bcl-2 family such as Bcl-2, Bcl-XL, 
and MCL1. Other apoptosis promoting proteins, known as Bcl-2 homology 3 – only (BH3-only) 
proteins, are unable to form channels in the mitochondrial outer membrane, however they bind 
and sequester the anti-apoptotic Bcl-2 factors thus preventing them from inhibiting Bax or Bak 
(26, 27). This sort of interrelation between the various types of Bcl-2 proteins allows for the 
integration of multiple stimuli to help regulate tissue homeostasis through apoptosis. DNA 
damage and errors during the cell cycle progression will lead to p53 activation (see Cell Cycle 
section),  which will in turn increase gene transcription of the pro-apoptotic Bax as well as the 
BH3-only PUMA and NOXA (28). This response is critical for the maintenance of DNA 
integrity or the prevention of oncogenic transformations as damaged cells are removed by 
undergoing cell death. Growth factor abundance is a strong survival signal, it negatively 
regulates programmed cell death trough Bcl-2 proteins. Downstream of growth factors binding to 
their respective receptors the Akt pathway is activated. Akt phosphorylates and inhibits BAD, a 
BH3-only factor, such post translational modification prevents the sequestration of the anti-
apoptotic Bcl-2 proteins and promotes survival (29, 30). Malfunctions of the p53 mediated DNA 
damage response and growth factor influenced PI3K/Akt pathways often contribute to 
tumorigenesis, as the organism loses the capability to remove these unwanted damaged cells 
which promotes the spread of the disease.  
As mentioned earlier a number of contributing factors also participate in programmed cell 
death, some interact with the elements of the caspase cascade while others act independently. A 
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family of proteins known together as inhibitors of apoptosis (IAPs) prevent caspase activation. 
Smac/Diablo factors are released into the cytoplasm following MOMP and inhibit IAP activity, 
thus enhancing the apoptotic program (22). AIF (apoptosis inducing factor) and endonuclease G 
also translocate from the mitochondria into the nucleus where they help degrade DNA (22). The 
relative importance of each individual component is subject to debate. It has been demonstrated 
that apoptotic cell death is possible in the absence of caspase actions, even though these event 
are morphologically different (22, 23). Interestingly while deactivation of apoptotic effectors 
Figure 3. The molecular regulation of caspase-dependent and independent apoptosis.  The 
intrinsic apoptosis pathway influences the permeabilization of the outer mitochondrial 
membrane. The consequent release of mitochondrial contents into the cytoplasm mediates both 
caspase-dependent and independent apoptotic responses. Ligand binding to the death receptor 
initiates the extrinsic pathway. Recruitment and cleavage of caspase-8 causes the downstream 
activation of effector caspases. 
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leads to a shift in the phenotype of apoptotic cell death, knock-out of both Bax and Bak renders 
cells apoptosis deficient and results in a switch to autophagy (20). 
 
2.2 Autophagy 
Autophagy is another form of programmed cell death that is generally initiated in 
response to nutrient starvation and involves the lysosomal degradation of cytoplasmic contents 
(31). Unlike apoptotic cell death autophagy at first is an attempt by the cell to recycle its contents 
when facing an energy deficit or cytotoxic stress. However, when excessive it results in cell 
death (32). Autophagy is a multistep pathway which involves a series of complex interactions 
between proteins encoded by the Atg genes (31, 33)(See Figure 4). These proteins guide the 
nucleation and maturation of the autophagosome, a double membrane vacuole which will 
enclose cellular contents destined to be degraded. Energy sensing pathways play a central role in 
the regulation of autophagy, with the antagonistic actions of AMPK and mTOR central in the 
control of the pathway induction (31, 33). Once upstream stimuli are activated the Atg6 (Beclin-
1 in mammalian cells) complex initiates vesicle nucleation and autophagosome formation (33). 
LC3 (also known as Atg8 in yeast) is activated through two protein conjugation systems and it 
completes autophagosome formation (33). This is followed by the fusion of the autophagosome 
with the lysosome and the degradation of the cargo it contains (31, 33). Autophagic cell death is 
primarily characterized by profuse engulfment of cytoplasmic portions (31, 33). 
The dynamic molecular mechanism of autophagy is increasingly more often implicated in 
states of health and disease. Upstream signals converge on the complex ULK1/2 the mammalian 
ortholog of Atg1 forms with multiple cofactors. This complex then phosphorylates components 
of the Beclin-1 complex to initiate the formation of the autophagosome (33). ULK1/2 and its 
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cofactors interact with mTOR which inhibits the initiation of autophagy. AMPK is activated in 
response to a high AMP/ATP ratio, it both inhibits mTOR and independently activates ULK1/2 
(33). The initial stages of autophagosome formation are mediated by the Beclin-1 complex. This 
step is influenced through numerous mechanisms which include transcriptional control, post 
translational modifications, and protein-protein interactions (33). Interestingly, Beclin-1 interacts 
with Bcl-2 as it has a BH3 binding domain, which serves as a point of cross-talk with the 
apoptotic pathways. This interaction is inhibitory and is alleviated during cellular stress 
conditions (33). The activation of LC3 is critical during the vesicle elongation and 
autophagosome maturation (33, 34). It is achieved through two interrelated systems that 
resemble ubiquitin-like conjugation. Briefly, Atg12 is covalently linked to Atg5, they then form 
a complex with Atg16. In turn, this complex will catalyze the conjugation of LC3 with 
phophotidylethanolamine (PE). This lipidation step converts the soluble LC3-I form into a 
membrane associated LC3-II state. Leading up to this step LC3 has to first be cleaved by Atg4 
then processed by the E1-like enzyme Atg7 and E2-like Atg3. Once the autophagosome is 
formed it will fuse with a lysosome to degrade its contents (33). The progress or flow of the 
autophagic pathway can be influenced in a number of different ways. Decreased upstream 
initiation will downregulate the flow through pathways, however reduced lysosome fusion will 
lead to accumulation of autophagosome intermediates. Deficiencies related to Atg genes also can 
impair the removal of unwanted cellular contents (31). Thus, unlike apoptosis where MOMP is a 
critical turning point, autophagy flux is somewhat difficult to discern. 
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Figure 4. The regulation of autophagy. The autophagy pathways consist of a number of distinct 
stages. The progress from one stage to the next (black dashed arrows) is regulated by the Atg 
proteins. AMPK and mTOR are cellular energy and nutrient sensing kinases that regulate the 
induction of autophagy through the ULK1 complexes. Beclin 1 complexes contribute to vesicle 




The skeletal musculature is a dynamic and highly regulated tissue that plays a pivotal role 
in mammalian functions. Muscle is generated by a series of complex events during embryonic 
development, and it also has the capacity to regenerate and restructure itself postnatally. Muscle 
cells originate in the somites, which are epithelial spheres formed from the paraxial mesoderm 
during the early stages of embryonic development (35). The dorsal region of the somites will 
then develop and form the dermomyotome which will be the source for most cells of the 
myogenic lineage (35). The dermomyotome is further subdivided into epaxial and hypaxial 
regions, which eventually form the myotome that will develop into trunk musculature (36). Other 
muscle progenitor cells will delaminate from the hypaxial dermomyotome and migrate to form 
the muscle of the limbs and the rest of the body core (36). 
Muscle development at the molecular level is regulated by a family of proteins known as 
the myogenic regulatory factors (MRFs) (reviewed in (37, 38)). The MRFs in turn are regulated 
by early myogenic determinants such as PAX 3 and 7 (37). Numerous studies outline distinct 
roles for the different MRFs and early myogenic factors as well as the hierarchy within the 
group. The first identified member of the MRF family, MyoD, was reported to have the capacity 
to convert fibroblasts and some other cell lineages into myoblasts (39). Myf5, another MRF, acts 
in a similar fashion (40). Mouse knock-out models with either of the genes missing appear to 
have relatively normal muscle development, with the other MRF compensating for the 
deficiency (41). Animals with both genes knocked out did not develop any skeletal muscle (41). 
The roles of Myf5 and MyoD within the developing embryo differ in a region specific pattern. 
While MyoD is the more prominent factor in muscles derived from the hypaxial region of the 
developing somite, Myf5 is important in the epaxial region (42). Myogenin is also capable of 
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converting a variety of cell types into myogenic cells (43). Moreover, downregulation of 
Myogenin prevents the late stages of myoblast maturation and fusion into multinucleated 
myotubes (35). Embryos with a deleted Myogenin gene die immediately after birth and they 
display severe defects such as reduced muscle size and lack of multinucleated muscle fibres (43). 
The role of MRF4 is somewhat disputed. Initially the protein was thought to regulate the later 
stages of muscle development, however some evidence argues that it might participate in earlier 
events as well (38). 
The actions of MRFs, or myogenesis in general, is further complicated by a number of 
additional levels of regulation. Those include transcriptional control of the myogenic regulators, 
post-translational modifications, chromatin remodelling, as well as protein-protein interaction 
(reviewed in (44)). The 4 MRFs are transcription factors that regulate the expression of genes 
required for myogenic development. They all contain a basic-helix-loop-helix (bHLH) domain 
which is essential for their function (45). The MRF proteins heterodimerize with ubiquitous non-
myogenic bHLH containing proteins such as E12 and E47, both products of the E2A gene, as 
well as a number of others, collectively termed E proteins. Once the heterodimer complex is 
active it binds to specific sites in the promoter regions of myogenic genes known as the E box 
(45). Proteins such as Id possess a HLH domain and are capable of binding to either MRFs or E 
proteins, however they do not activate gene transcription. Thus, the presence of such proteins 
dilutes the amount of MRFs and E proteins that would be available to associate with each other 
and activate muscle gene expression (45). The MRF/E protein heterodimer will further form a 
complex with other coactivators such as the histone acetyltransferaces p300 and PCAF. These 
complexes will then recruit the transcriptional machinery in addition to affecting chromatin 
remodelling (45). The Myocyte Enhancer Factor-2 (MEF2) family of MADS-box transcription 
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factors is another class of proteins that activate the expression of myogenic genes (reviewed in 
(46)). The MADS-box motif is required for DNA binding, while the MEF2 domain increases the 
DNA binding affinity and participates in protein-protein interactions (46). Although it is 
questionable if MEF2 proteins are capable of evoking myogenic determination on their own, 
their cooperation with the MRF proteins is well established. In fact, often the MEF2 and E box 
sites on the promoters of muscle specific genes are located in close proximity. MEF2 proteins 
physically interact with the bHLH regions of the MRFs and synergize in the activation of the 
myogenic program (46). MyoD and the other MRFs are also regulated at the post translational 
level through both phosphorylation and acetylation (45). Ultimately, this complex network of 
molecular mechanisms converges on MRF controlled gene expression to help shape the 
myogenic program which guides the development and maintenance of skeletal muscle tissue.  
 PAX3, and to some degree PAX7, are believed to act as key early myogenic regulators. 
It was demonstrated that PAX3 is able to activate the expression of both Myf5 and MyoD (47). 
Moreover, cells expressing PAX3 and/or PAX7 are a key contributor to all skeletal muscle. 
Knock out of both these genes results in arrest of muscle development (48). While promoting the 
early events of the myogenic program, PAX3 supresses the late stages, and it must be 
downregulated to allow myogenic cells to undergo terminal differentiation (49). PAX3 
cooperates with and also regulates a number of factors that help promote the myogenic program. 
SIX transcription factors family and their cofactors EYA proteins participate in the activation of 
the MRFs (37). In addition, Msx1 helps ensure adequate expansion of the myogenic progenitors 
by inhibiting differentiation (37). The c-Met receptor and its ligand HGF (hepatocyte growth 
factor), as well as Lbx1 are required for proper migration of the myogenic cells to the limb 
regions of the developing embryo (37). 
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Throughout the embryogenesis a number of secreted factors control the spatio-temporal 
patterns of skeletal muscle development. Shh, a factor released from the notochord, together with 
the Gli transcription factor promotes myogenesis through upregulating Myf5 expression (38). 
BMP (bone morphogenic protein) is antagonistic to the actions of Shh (35). Furthermore, Wnt 
factors are released from the neural tube and surface ectoderm and are also important regulators 
of myogenesis (38). Notch and its ligand Delta inhibit MyoD, while fibroblast growth factors 
(FGF) are also implicated in the regulation of MRFs (36). These morphogens collectively 
influence the myogenic program to control orderly tissue patterning in the developing organism. 
Once functionally mature, muscle tissue still has the capability to regenerate and 
restructure following certain event such as injury or training (44). By and large, this response is 
mediated by a population of myogenic progenitor cells known as satellite cells (reviewed in 
(50)). Other muscle residing stem cells as well as bone-marrow derived stem cells also contribute 
to the regeneration process, albeit to a lesser degree (50). The satellite cells reside within the 
basal lamina which surrounds muscle fibres, and are mitotically quiescent during normal 
conditions (50). During the process of regeneration satellite cells re-enter the cell cycle, undergo 
multiple rounds of cell division, they then proceed to the differentiation step and fuse with the 
existing muscle fibres (44)(See Figure 5). Some of the daughter cells created during the 
proliferation stage do not differentiate and fuse, but rather revert back into the quiescent state to 
replenish the progenitor pool (50). Irradiation or treatment with drugs that prevent cell division 
debilitates muscle regeneration following injury (50). Once activated, satellite cells start 
expressing MRFs which control the myogenic program (44). Out of the four MRF family 
members, MyoD is reported as essential for proper myogenic stem cell function in adult skeletal 
muscle (51). PAX7 appears to play an important role in those cells, since animals with this gene 
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mutated display lack of satellite cells and reduced muscle size (52). A number of growth and 
inflammatory factors secreted in the muscle tissue appear to promote myogenesis, those include 
HGF, FGF, IGF and LIF (50). The TGF-β family of proteins, which includes myostatin, inhibit 
the proliferation and differentiation of satellite cells (50). Similar to muscle formation in 
embryogenesis the execution of the separate events must be properly timed. The satellite cells 
must proliferate to adequately expand their population, while excessive or insufficient cell 
number will compromise tissue healing. Furthermore, following the initial proliferative stage the 
myogenic progenitor cells switch to differentiation then they must fuse with the damaged muscle 
fibres. This stage is also critical to skeletal muscle maintenance, while deficiencies often lead to 
degenerative conditions such as muscular dystrophy (50). 
 
3.1 Cell cycle in Myogenesis 
Regulation of the cell cycle is an essential part of the myogenic program (reviewed in 
(53)). Muscle precursor cells must halt cellular replication to allow differentiation. During the 
Figure 5. Stages of satellite cell recruitment and myogenic regulators. Quiescent satellite cells once 
activated begin to proliferate in order to expand the cell population. Differentiating satellite cells 
must first exit the cell cycle, once terminally differentiated these cells fuse into multinucleated 




final stages of muscle cell maturation they will irreversibly exit the cell cycle and reach a state of 
terminal differentiation. Following that, myoblasts fuse with muscle fibres or form syncytial 
myotubes (53). These events are controlled by a complex regulatory network that involves MRFs 
and cell cycle regulators. Myf-5 and MyoD, the MRFs implicated in myogenic determination, 
undergo distinct cell cycle dependent regulation (54). Myf-5 protein levels are notable in G0, the 
quiescent state, and are downregulated as cells proceed through G1. Conversely, the MyoD 
protein is highly expressed during G1 and its levels diminish as cells near the G1/S transition 
(54). Knock-out studies revealed that Myf-5 deficient cells undergo premature differentiation, 
which is accompanied by higher than normal myogenin gene expression together with other late 
muscle specific markers (55). Furthermore, MyoD-null cells fail to proceed in their myogenic 
program (55). Induction of MyoD expression is known to act as a potent inhibitor of cell 
proliferation (56). In fact, myogenic stem cells lacking MyoD continue proliferating but fail to 
undergo further development (51). Inefficient MyoD activity is an underlining characteristic of 
rhabdomyosarcomas which are characterized by over-proliferation (57). 
Since cell cycle arrest is necessary for muscle differentiation, conditions that boost 
replication also prevent muscle gene expression. Either overexpression of E2F1 (58), or knock-
out of its inhibitor Rb (59) abolish the differentiation of myoblasts. Moreover, as myogenic cells 
progress towards terminal differentiation E2F expression is downregulated (58). Also, Rb protein 
levels are increased through direct transcriptional activation by MyoD (60). Hence, regulators of 
the Rb/E2F axis, such as CDKs and CKIs, inevitably have effects on the differentiation program 
in muscle progenitors. Most of the interphase CDKs and cyclins are reported to be 
downregulated as cells stop proliferating and begin expressing muscle specific genes (53). p21 is 
a well characterized MyoD target gene and its expression is increased to allow terminal 
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differentiation independently of p53 signalling (61). Animals with p21 and p57 genes both 
knocked-out display severe muscle deficiencies (62). p27 is also expressed in the developing 
musculature and it enhances MyoD activity (63).  
Besides regulating myogenic differentiation through the Rb/E2F pathway at the G1/S 
transition point, many of the cell cycle regulators are reported to also participate in regulation of 
MRF activities through protein-protein interactions and post-translational modifications. The Rb 
protein directly binds to MyoD and this interaction is reported to promote muscle cell 
commitment and differentiation (64). CDK4 binds to MyoD and prevents its DNA binding 
ability (65). Cyclin D is required for nuclear import of CDK4 where the interaction between the 
two proteins takes place (65). Conversely, CDK4 kinase activity is also inhibited when it is 
bound to MyoD (66). CDK1 and CDK2 where shown to phosphorylate MyoD on serine 200 and 
this post-translational modification inhibits its activity and promotes degradation (67).  p57 acts 
to inhibit the CDK2 and CDK1 complexes and it is thought to also directly bind and stabilize 
MyoD (68). The reciprocal interaction of MyoD with positive cell cycle regulators and its 
cooperation with cell cycle inhibitors highlights the vital role this MRF plays in the transition 
from proliferation to myogenic differentiation. These interactions also help elucidate why muscle 
gene expression is normally absent during the proliferative stages. 
 
3.2 Regulation of Myogenesis  
The effectors of myogenic and cell cycle processes are regulated through a number of 
signal transduction pathways. These signalling sequences integrate the various external stimuli 
and internal cues and comprise of a series of post-translation modifications often carried out by 
protein kinases. Amongst the most researched and established pathways implicated in the 
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myogenic process are the mitogen activated protein kinase (MAPK) family (69) and the PI-3 
Kinase (PI3K) (70) signalling cascades. Both of these pathways play a role in the proliferation 
and differentiation stages. Extracellular signal regulated kinase (ERK), a member of the MAPK 
family, is a well characterized regulator of cell proliferation (reviewed in (71)). Following the 
binding of mitogenic factors to their respective receptors on the cell membrane Ras activation is 
triggered. Raf, a downstream target of Ras, is a kinase that activates MEK which consequentially 
phosphorylates ERK1 and ERK2 (71). ERK1/2 in turn promotes activation of Fos and Jun, both 
being components of AP-1 transcription factor, and induces Cyclin D gene expression (71). 
ERKs also stabilize the c-Myc factor which plays an important role in regulating cell cycle 
progression (71). Active MEK1 was shown to block the activity of the nuclear MyoD 
transcriptional complex, potentially through direct protein-protein interaction (72). Fos and Jun 
are reported as inhibitors of transcriptional activation of myogenic genes by MyoD and 
Myogenin (73). In addition, c-Myc possesses a bHLH domain and was shown to repress MyoD 
initiated differentiation as well (74). The protein kinase Akt is thought to influence both 
proliferation and myogenic differentiation. The numerous targets downstream of Akt participate 
in various essential cellular functions, some of which were shown to have an impact on the state 
of myoblast cells. The PI3K/Akt pathway is activated following mitogenic stimulation, and it is 
thought to enhance the G1/S cell cycle progression (75). Akt regulates p27 protein localization 
within the cell. Following phosphorylation of the T157 residue the CKI is then trapped in the 
cytoplasm, and thus unable to inhibit the nuclear CDK complexes (76). In addition, Akt is also a 
negative regulator of FOXO activity. The FOXO transcription factors are responsible for 
upregulating p27 gene expression (77), while reducing Cyclin D levels (78). GSK3β is 
inactivated by Akt which makes it unable to tag Cyclin D for degradation (79). The mTOR 
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complex, a well characterized Akt target is also a positive cell cycle regulator (80). Altogether, 
both ERK and Akt signalling pathways cooperate to promote G1/S stage transition, hence 
promoting the proliferation and inhibiting the differentiation of myogenic progenitors. This step 
is responsible for the proper expansion of the muscle progenitor pool prior to differentiation and 
fusion.  
Upon initiation of differentiation myoblasts exit the cell cycle and induce the activity of 
myogenic regulators. Those events are coordinated through the p38 MAPK and PI3K/Akt signal 
transduction pathways. Inhibition of either one results in abrogation of myogenic differentiation 
(81). p38 kinase activity increases over the course of differentiation and it promotes cell cycle 
exit and expression of late myogenic genes (82). PI3K/Akt signalling is thought to downregulate 
the MAPK/ERK pathways as myoblasts switch from proliferation to differentiation (83). 
Inhibition of ERK signalling normally accompanies muscle differentiation, while deactivation of 
this pathway promotes expression of myogenic genes (84). GSK3β is target of Akt directed 
inhibitory phosphorylation and it is reported that deactivation of GSK3β induces myogenic 
differentiation (85). Furthermore, Akt is an important mediator of cell survival. Inhibition of this 
enzyme in differentiating myoblasts is reported to impair survival (86). Calcium regulated 
signalling is another emerging regulator of myogenesis. Reduction of intracellular calcium levels 
attenuates the differentiation of myocytes (87). The Calcineurin/NFATc pathway is a potential 
mediator of calcium signalling with its upregulation promoting the expression of myogenic genes 
(88). Calcineurin is a calcium/calmodulin regulated phosphatase that removes a phosphate group 
from the NFATc transcription factors, which is essential for their nuclear localization (88). 
Interestingly, the actions of Calcineurin upon NFATc3 are antagonized by GSK3β, with 
inhibition of GSK3β overcoming the blockade of myogenic differentiation caused by Calcineurin 
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suppression (89). Furthermore another calcium regulated enzyme, Calcium/calmodulin 
dependent kinase (CaMK), is a major positive regulator of MEF2 DNA binding ability (90). The 
enzymes involved in the regulation of myogenesis could potentially be targeted by therapeutic 
interventions to alter the course of the muscle tissue maintenance.   
 
3.3 Electrical Stimulation of Muscle Cells 
The electrical stimulation model was originally developed to mimic the innervation of 
muscle tissue, to help study the effects of depolarization induced contractile activity (reviewed in 
(91)). It is known to evoke a wide range of cellular responses within the muscle fibres. However, 
it also promotes the activation of satellite cells and their fusion with those muscle fibres (91). In-
vitro use of electrical stimulation on myoblast cells, as well as differentiated myotubes, is a 
helpful tool in identifying specific signalling events involved in the various phenotypical changes 
observed with the use of this model (91, 92). Cell cycle arrest is one of the changes elicited by 
electrical stimulation in myoblasts (93). It is accompanied by increased protein levels of MyoD 
and markers of mitochondrial biogenesis, which points to the induction of myogenic 
differentiation (93). Those changes appear to be mediated through AMPK activity downstream 
of calcium signalling (93). AMPK is a well-known regulator of cellular energy balance and it is 
thought to inhibit proliferation during energy deficient states (94). Activated AMPK is reported 
to phosphorylate p27 on T198 and increase its protein stability (95). In fact, electrically 
stimulated myoblasts displayed higher p27
T198
 and total p27 protein levels, as well as an 
increased amount of cyclin E bound to p27. Moreover, these changes were attenuated following 




Cancer is a disease characterized by progressive transformation of normal cells within an 
organism into malignant derivatives (96). Tumorigenesis in its essential form is fuelled by 
dynamic genomic changes that produce continuous and uncontrollable growth and expansion of 
malignant cancer cells (96). The majority of tumors are genetically unstable. As a result they 
accumulate mutations in oncogenes and tumor suppressor genes, which promote the clonal 
expansion of those cells (97). Cancer cells acquire a number of capabilities that are essential to 
pathogenesis of the disease including self-sufficiency in growth signals, insensitivity to anti-
growth cues, ability to evade apoptosis, limitless replicative capacity, sustained angiogenesis, 
and the ability to metastasize and invade other tissues (96). Furthermore, the tumor mass can be 
characterized as an organ that contains a heterogeneous population of cells, which all contribute 
to the creation of a microenvironment that reinforces cancer development (98). Uncontrolled cell 
proliferation seen in cancer cells is caused through continuous deregulated entry and inability to 
exit the cell cycle (99). Many mechanisms that drive cancer progression converge on Rb/E2F 
axis and its regulation (100). Given the importance of Rb mediated repression of the cell cycle in 
normal cellular functions, it is not surprising that many of the regulators of this pathway are 
implicated in cancer. p27 deregulation and Cyclin D over-activation are common culprits of 
uncontrolled proliferation seen in a large number of cancers (101). In the big picture, the G1 
stage of cell cycle is a period when a wide range of signals determine the fate of cell growth and 
proliferation. Deregulation within this stage and its many components plays a crucial role in the 
onset and progression of malignant growth (101). Underlying this deregulation are proliferation 
promoting pathways such as Ras/ERK and PI3K/Akt which are often hyper activated in 
cancerous cells (101). Healthy cells have built-in mechanisms that ensure the integrity of the 
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DNA before proceeding to further cell cycles phases. Progress will be halted and DNA repair 
initiated as a consequence of genomic damage and cell death pathways are often activated if 
those repairs fail (see above). Cancer cells are often defective in the control of these checkpoints 
leading to the inability to prevent progressive DNA damage and the resultant genomic instability 
characteristic to cancers (15). The dynamic nature of the disease in turn contributes to the 





Rhabdomyosarcoma (RMS) is a form of cancer where tumor cells have characteristics of 
myogenic heritage (reviewed in (102)). These cells initiate the myogenic program but fail to exit 
the cell cycle and do not undergo terminal differentiation (57). Unlike most tumors, 
rhabdomyosarcoma affects mostly children and adolescents. Pathologically, this cancer can be 
subdivided into 3 distinct variants. The embryonal form (eRMS) most often affects young 
children, it commonly arises in the head and neck, paraspinal region and the genitourinary 
system (103). The alveolar form (aRMS) mostly localizes to the extremities and axial 
musculature (102, 103). The third pleomorphic form affects the musculature of adults and is a 
rare event (102).  A portion of the alveolar rhabdomyosarcoma tumors carry a well-defined 
genetic mutation, a chimeric gene is formed through fusion of 2 regions from separate 
chromosomes and it is thought to drive the malignancy (104, 105). A portion of a gene for the 
Forkhead (FKHR) family member FOXO1 located on the 13th chromosome translocates into the 
region encoding either PAX 3 on chromosome 2, or PAX7 on chromosome 1 (104). aRMS 
tumors negative for the fusion gene are clinically and  molecularly indistinguishable from the 
eRMS forms (106). Furthermore, recently published outcomes of whole genome analyses of a 
large set of RMS samples demonstrate that based on molecular signatures all RMS tumors can be 
categorized into two groups, defined by the either presence or absence of the fusion gene (107). 
The variants of rhabdomyosarcoma have different prognostic fates. The PAX3/FOXO1 fusion 
positive tumors are associated with the least favourable outcome followed by PAX7/FOXO, 
while fusion negative aRMS and eRMS are statistically linked with a lesser risk of mortality 
(108). This risk stratification is important to identify and prioritize treatment strategies and 
research efforts. Despite continuous advances in our understanding of this disease severe cases 
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are still linked to high death rates and future research is essential for improvements to these 
outcomes.  
The characterization of RMS cells as both cancerous and myogenic has led to extensive 
study of the molecular properties that produce such unique state. At the genomic level, there are 
identifiable abnormalities that contribute to the pathology of rhabdomyosarcoma. Even though 
aRMS is often associated with the distinct PAX/FOXO1 chromosomal translocation, eRMS 
tumors exhibit a common underlying genetic signature as well. Loss of heterozygosity on a 
specific locus on the 11th chromosome is a frequent characteristic of the rhabdomyosarcoma 
tumor genotype (109). This region contains a number of imprinted genes that could potentially 
act as drivers of the malignancy, those include H19, p57Kip2, IGF2 and a number of others 
(110). A familial germline mutation in the p53 gene, called Li-Fraumeni Syndrome (LFS), is 
often associated with increased incidence of pediatric cancers (111). A number of young RMS 
patients are reported to have this familial disorder, while some others exhibit de-novo p53 
mutations (111).  MyoD, an important regulator of muscle formation, is expressed in 
rhabdomyosarcoma cells but does not initiate terminal differentiation. It is reported that the 
MyoD protein is capable of binding to DNA, however its transcriptional activation abilities are 
deficient in both eRMS and aRMS (112). This evidence suggests that a factor required for the 
activation of MyoD activity is deficient in those cells (112). Indeed, forced dimerization of 
MyoD with E proteins promotes differentiation of RMS cells (113). Furthermore, MEF2D 
expression is reported to be downregulated in some RMS cases and exogenous reinstatement of 
this protein enhances myogenic differentiation and inhibits tumorigenicity (114). aRMS 
associated PAX/FOXO1 fusion proteins prevent MyoD transcriptional activity, though it appears 
that this mechanism is independent of the MyoD-E protein interaction (115). As discussed earlier 
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MyoD, is crucial for cell cycle exit and induction of differentiation in myogenic progenitors (see 
Myogenesis section). Hence, it is not surprising that RMS cell continue to proliferate 
uncontrollably and that it coincides with impaired MyoD mediated transcriptional activity. These 
deficiencies pose a challenge for therapeutic approaches that would target myogenic 
differentiation signalling to help induce cell cycle arrest in RMS cells.   
Examination of the PAX/FOXO1 fusion gene properties has yielded a better 
understanding of the contribution of this chromosomal translocation to tumor development. The 
ability to activate transcription of target genes due to PAX DNA-binding domain interaction with 
specific promoters is more potent when fused with the transactivation domain of FOXO, 
compared to wild type (116). The expression of the PAX/FOXO gene itself is amplified in 
rhabdomyosarcoma which leads to accumulation of the protein (117). Moreover, the chimeric 
protein interferes with the activity of wild type PAX3 in developing muscle progenitors (118). 
When PAX3/FOXO is expressed ectopically in fibroblasts the cells acquire a number of 
tumorigenic characteristics (119), underlining the enhancement of proliferation and invasiveness 
of cancer cells (120). In contrast, downregulation of PAX3/FOXO protein expression promotes 
cell cycle arrest, induction of myogenic differentiation and also cell death in RMS cells (121, 
122). Targeting the fusion gene product directly, through altering either the upstream regulators 
or downstream effectors could serve as a strategy for possible therapeutic interventions in this 
subtype of RMS tumors.       
Despite the obvious muscle resemblance, research has yet to clearly establish which cells 
in the body give rise to RMS (reviewed in (123)). A portion of RMS tumors are located in and 
around the skeletal muscle, however some also develop where muscle tissue is generally absent. 
To accentuate the variability in the origin of RMS cells, tumors were shown to develop from 
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both committed myogenic progenitors as well as uncommitted mesodermal cells (123). These 
inconsistencies raise the question of whether RMS are in fact muscle cells that fail to 
differentiate or if they are cancer cells which acquire some myogenic properties. Primary tumor 
samples, in-vitro cell culture and in-vivo animal models of RMS help researches address this 
question and uncover the underlying molecular properties of these tumors. Commonly used cell 
lines are the eRMS RD line and the aRMS Rh30. The RD line was established from a biopsy 
from a refractory tumor in the pelvic region of a 7 year old female patient who has previously 
undergone chemotherapy and radiation therapy. This cell line is reported to carry a MYC 
amplification, as well as Ras and p53 mutations (124). The Rh30 line contains the PAX3/FOXO 
fusion gene and was established from a bone marrow metastasis sample from a previously 
untreated 16 year old male. These cells carry a heterozygous p53 mutation and amplification on 
the 12
th
 chromosome in a region containing CDK4 (124). Neither cell line originated from a 
sample taken in a body area where skeletal muscle in generally found, however both clearly 
exhibit the myogenic signatures characteristic to RMS. The heterogeneous origins of RMS call 
for categorization that is based on the molecular properties rather than the localization of those 
tumors.  
 Interestingly, ectopic insertion of the PAX3/FOXO fusion gene under the wild type 
PAX3 promoter does not lead to tumorigenesis in-vivo. Rather, abnormalities in embryonic 
development similar to a PAX3 deficiency arise, which suggests that the PAX3/FOXO fusion 
gene negatively affects normal PAX3 function (125). However, as demonstrated by Keller et al., 
conditional PAX3/FOXO knock-in into differentiating muscle cells aided by INK4a/ARF and 
p53 loss of function led to aRMS development in-vivo (126). Hence, the fusion protein likely 
cooperates with a number of secondary mutations to produce a malignant in-vivo tumor (126, 
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127). According to whole genome scans, a portion of aRMS tumors carry common chromosomal 
amplifications and deletions that possibly alter the expression of cell cycle regulators. Also, 
fusion gene positive aRMS samples appear to undergo genetic mutagenesis to a lesser extent 
than the fusion gene negative or the eRMS subtype (107). Therefore, the molecular signature of 
the fusion gene positive aRMS tumors outside of presence of PAX/FOXO is not as clearly 
identifiable as in eRMS.  
Sharp et al. in 2002 created an in-vivo eRMS model by overexpressing the HGF/SF 
(hepatocyte growth factor/scatter factor) in INK4a/ARF knockout mice (128). INK4a is an 
inhibitor of CDK4 and is implicated in Rb regulation while ARF represses MDM2, a negative 
regulator of p53. HGF/SF is a ligand of c-Met, a receptor tyrosine kinase (RTK) which upon 
binding activates Ras signalling downstream (128). Amongst eRMS tumors cell cycle checkpoint 
regulation is often deficient and Rb mutations are a common example of that (57, 105, 129). A 
number of other studies show that some form of Ras pathway deregulation together with p53 
deficiency will lead to RMS development in-vivo (130-133). Numerous RTK are implicated in 
eRMS tumorigenesis, these include FGFR, IGFR, PDGFR (134, 135). Mutations in Ras genes 
are also common in this malignancy (107, 133). In a separate study, Shh (sonic hedgehog) 
pathway deregulation in mice was shown to lead to eRMS development in a non-myogenic cell 
lineage (136). Ptch1 is a negative regulator of Shh and heterozygous deletion of this gene 
contributed to the transformation of myogenic progenitors into eRMS cells (129). Furthermore, 
in human samples hyper-activation of the Shh pathways is associated with a less favourable 
prognosis (137). Overall, examination of animal models as well as human samples identifies 
common patters in eRMS pathogenesis. Deregulation of the RTK/Ras pathway, deficiency in 
p53 signalling and hyper-activation of the Shh are drivers of fusion negative RMS development 
33
and those are in turn aided by deregulation of Rb and possibly other cell cycle checkpoint 
pathways. 
The Akt pathway is an intriguing target in RMS research as it plays a role in both cell 
proliferation and survival, as well as myogenic differentiation. Increasing Akt activity may 
promote pro myogenic events, which in turn could potentially lead to reduced tumorigenicity. 
However, inhibition of this pathway might help reduce proliferation and induce cell death in 
RMS cells. Dissecting the specific roles played by the targets of this kinase in RMS oncogenesis 
will likely help determine which option is best for therapeutic intervention. As discussed earlier, 
the PI3K/Akt pathway is a potent pro-survival mediator (see Programmed Cell Death Pathways 
section). Also, it was demonstrated that the mTOR complex inhibitor, rapamycin, prevents 
proliferation of RMS cells and induces p53-independent cell death (138). mTOR activity is 
positively regulated by Akt mediated phosphorylation (139) and recently emerging evidence 
shows GSK3 inhibition elicits favourable consequences in both the embryonal and alveolar RMS 
forms (140-142). Since Akt phosphorylates and inhibits GSK3 (139), increased Akt activity may 
result in desirable tumor inhibiting effects. The most captivating target of Akt in the RMS 
context is perhaps FOXO. FOXO1 is known to be mislocalized out of the nucleus following 
phosphorylation by Akt on 3 separate residues (143). However, despite the fact that 2 of those 
residues are present in the chimeric protein product of the PAX/FOXO1 gene, it is not responsive 
to Akt mediated regulation (143). This finding was challenged by Jothi et al. who showed that 
Akt does in fact modulate the activity of the fusion gene (144). Activation of Akt is reported to 
promote arrest of proliferation and cell death in aRMS cells (140, 145). Evidence helps argue 
that inhibition of Akt is in some aspects beneficial in lessening the oncogenic properties of RMS. 
In contrast, activation of this pathway is also shown to weaken the RMS phenotype. The relative 
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importance of Akt targets is hard to specifically identify as their activity encompasses such a 
broad range of cellular functions. Ultimately, in light of the conflicting outcomes to varying Akt 
activity in RMS cells, the roles of the individual Akt targets could be further investigated as 
opposed to the comprehensive function of the pathway.  
The regulation of myogenesis, as previously discussed, is complex and involves a number 
of signalling pathways. Targeting some of those molecular mechanisms could potentially be 
beneficial in offsetting the RMS phenotype. Since muscle differentiation is coupled with cell 
cycle arrest, inhibition of signalling sequences involved in proliferation could potentially induce 
differentiation in RMS. For instance, Cyclin D/CDK4 complexes promote G1 phase progression 
and inhibit MyoD activity, while pharmacological inhibition of the complex arrests proliferation 
in RMS cells (146). Also, both ERK and Akt signalling are well known mediators of myoblast 
proliferation (see Myogenic Signalling section). Studies show that concurrent inhibition of both 
MAPK/ERK and Akt/mTOR in RMS cells yields a synergetic interaction detrimental to the 
growth of these tumors, in comparison the inhibition of either pathway individually is rather 
inefficient (147, 148). Conversely, p38 signalling is critical to the myogenic differentiation 
process since it contributes to cell cycle arrest. Forced activation of p38 in rhabdomyosarcoma 
cells resulted in an increased expression of late myogenic genes that are usually absent in the 
malignant state (149). In support of this line of evidence, inhibition of Notch is reported to result 
in p38 activation and the consequent differentiation events (150), while Notch hyper-activation 
in RMS samples is shown to yield a more aggressive tumor phenotype (151). Despite the 
potential of pharmacologically targeting these pathways in experimental settings, the 
incorporation of such drugs into comprehensive patient treatment strategies is complicated. 
Issues such as toxicity, bioavailability, and targeted delivery all limit the possible applicability of 
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such therapies. Furthermore, RMS patients are often children who must still biologically develop 
and mature, drugs could also potentially interfere with this crucial aspect.   
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6. Hypotheses  
My research will center around the use of the in-vitro electrical stimulation model on 
rhabdomyosarcoma cells. The ultimate goal of the project is to investigate whether the myogenic 
properties of those cancerous cells could be manipulated in a way similar to healthy myoblasts. 
The central tenet of my thesis is that electrical stimulation of rhabdomyosarcoma cells will elicit 
growth arrest and potentially promote myogenic differentiation. This could be further broken 
down into the following specific hypotheses:  
1. Electrical stimulation of RMS cells will activate AMPK and induce cell cycle arrest, a 
response analogous to that seen in myoblasts.  
2. Electrical stimulation will induce myogenic differentiation in RMS cells. 
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Rhabdomyosarcoma (RMS) is a soft tissue cancer that manifests in young patients and 
demonstrates muscle-like properties. Unlike muscle cells, RMS cells fail to undergo cell cycle 
arrest and terminal differentiation despite the presence of the necessary molecular regulators to 
do so. Electrical stimulation (ES) elicits a variety of phenotypical changes in skeletal muscle, and 
we set out to determine whether ES induces any effects in RMS cells. Both alveolar (Rh-30) and 
embryonal (RD) RMS cells were subjected to ES (5Hz, 5V) for 4 hours/day followed by a 20 
hour rest period for 1-5 days. ES of RD and Rh-30 cells led to a reduction in the number of cells 
and an altered phenotype when compared to non-stimulated control (CTL) cells. FACS analyses 
revealed that ES induced an accumulation of RD and Rh-30 cells in the G2/M phase of the cell 
cycle. ES also increased the conversion of LC3-I into LC3-II which suggests an increase in 
autophagy. Furthermore, ES induced the phosphorylation of Akt/PKB on T308, important for 
cell survival and myogenic differentiation, while protein levels of MyoD and myogenin were 
also altered by ES in RMS cells. Thus, it appears that electrical stimulation of 
rhabdomyosarcoma cells leads to cell cycle arrest and cell death, which potentially provides the 




Rhabdomyosarcomas (RMS) are a family of juvenile soft-tissue cancers that express 
many of the molecular factors that regulate muscle maturation (103, 152). RMS tumors are 
subcategorized with two main forms being embryonal (eRMS) and alveolar (aRMS)(152). RMS 
origins are highly heterogeneous, eRMS often affects young children and presents in the head 
and neck, the paraspinal region and the genitourinary system. In contrast, aRMS tumors mostly 
localize to the extremities and axial musculature and generally develop in adolescents (103, 152). 
A portion of aRMS tumors carry a chromosomal fusion between genes encoding either PAX3 or 
PAX7 and the Forkhead family member FOXO1. The resultant chimeric PAX/FOXO protein is a 
potent transcription factor which is thought to induce the aRMS malignant phenotype (57, 104, 
152). Fusion gene positive aRMS are associated with the high mortality rates, while fusion gene 
negative aRMS are indistinguishable from eRMS (106, 108, 152).  Activating alterations in 
receptor tyrosine kinases and ras signalling pathways as well as dysfunctions in developmental 
patterning pathways and cell cycle regulation are all evident in RMS patients (57, 107). This vast 
range of oncogenic properties makes identification of a singular molecular therapeutic 
intervention in RMS patients extremely difficult.  
Maintenance of multinucleated skeletal muscle mass is assisted by muscle derived stem 
cells, termed satellite cells (50). Following nuclear degeneration or muscle damage, quiescent 
satellite cells first proliferate to increase their numbers and subsequently undergo differentiation 
and fusion by inducing the expression of myogenic regulatory factors (MRFs) (37, 50, 153). 
MRFs heterodimerize with E proteins to activate the transcription of myogenic genes (45). One 
of these MRF, MyoD, is indispensable for proper myogenic stem cell function (51). MyoD 
increases p21 expression to promote cell cycle exit in myoblasts (53, 61). The importance of 
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MyoD in muscle regeneration is illustrated by rendering satellite cells differentiation 
incompetent in MyoD
-/-
 mice or in-vitro (51, 55). Unlike other cancers, RMS cells express MRFs 
and many other genes unique to myogenic progenitor cells, however unlike myoblasts they fail 
terminally differentiate due to lack of MyoD transcriptional activity (112, 113). What remains 
unclear is whether RMS originates from myogenic cells with a disrupted differentiation program, 
or if they are primarily tumor cells that somehow acquire muscle-like characteristics. Regardless 
of the reason, these myogenic properties may allow for the induction of cell cycle exit and 
terminal differentiation in RMS cells.  
Electrical stimulation (ES) is an effective method whereby to induce a wide range of 
phenotypical changes in excitable cells including skeletal muscle and neuronal cells in-vivo and 
in cell culture (91, 92). Earlier findings from our lab demonstrate that when electrically 
stimulated myoblasts exit the cell cycle due to the activation of AMPK and the subsequent direct 
phosphorylation of the CDK2 inhibitor p27
KIP1
 on T198, leading to its accumulation in the cell. 
This increase in p27 protein levels caused cell cycle arrest and differentiation of the myoblasts in 
culture (93). Based on these results we electrically stimulated eRMS and aRMS cells to evaluate 
whether ES of those cells will activate the myogenic program and induce cell cycle exit and 
differentiation. We show that stimulation of eRMS and aRMS cell leads to a drastic reduction in 
cell numbers. In response to ES there appears to be no activation of pathways that induce G1 
arrest in these cell types, suggesting an involvement of alternative mechanism. In agreement with 
this FACS analyses revealed an accumulation of RMS cells in G2/M and an enhancement in the 
activation of LC3 a critical regulator of autophagy. These effects are accompanied by an increase 
in Akt activity as protein levels of the T308 phosphorylated form are elevated in both RMS cell 
lines in response to ES. Overall, our findings suggest that electrical stimulation reduces 
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proliferation and induces autophagy in RMS cells and may provide a novel therapeutic avenue 




7.3. Materials and Methods 
Cell Culture. RD (eRMS) and Rh-30 (aRMS) cells were a generous gift from Dr. John 
McDermott (York University, Toronto, Ontario) and were maintained at 37
o
C and 5% CO2, in 
high glucose Dulbecco’s Modified Eagle’s Medium (DMEM, Wisent, St.Bruno, Quebec), 
supplemented with 10% fetal bovine serum and 2% antibiotic-antimycotic solution (Wisent). The 
media was replenished every 48 hours.  
Electrical stimulation. Cells were plated onto 0.1% gelatin coated 6 well plates. Cells that 
were stimulated for a longer duration were plated at a higher density to account for cell loss. The 
lids of the plates were fitted with two parallel platinum wire electrodes, placed at the opposite 
ends of each well and extending into the media. The wires from all wells were arranged in 
parallel and connected to an electrical stimulator (Harvard Apparatus Canada, Saint-Laurent, 
Quebec, Canada). Cells were stimulated at 5V and a frequency of 5Hz for 4 hours/day with 
alternating potential followed by a 20 hour recovery period for 1 to 5 days. Cells were harvested 
following the recovery period throughout the protocol in 0.2% TENT buffer (TRIS, EDTA, NaCl 
and 0.2% Triton x-100) supplemented with phosphatase inhibitor (phosSTOP, Roche 
Diagnostics, Laval, Quebec) and protease inhibitor (Sigma, Oakville, Ontario).  Samples were 
then sonicated and centrifuged (16,100x g), the supernatants were collected and stored at -84
o
C 
for subsequent analyses. 
Western Blot. Protein concentrations in the samples were determined using the Bradford 
assay (Bio-rad, Mississauga, Ontario). 25µg of each sample was loaded onto a 12% 
polyacrylamide-SDS gel, separated via electrophoresis and transferred onto a PVDF (Bio-rad). 
Following blocking in 10% skim milk, membranes were incubated overnight with primary 
antibodies for pAkt
T308
 (1:500), Akt (1:2000), pAMPK
T172
 (1:1000), AMPK (1:1000), , 
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pGSK3βS9 (1:1000), GSK3β (1:1000)(Cell Signaling, Whitby, Ontario); p27T198 (1:1000) (R&D 
Systems, Minneapolis, MN); p27(1:2000)(BD Biosciences, Mississauga, Ontario); Cyclin E 
(1:2000), COX IV (1:5000), Myogenin (1:500), β-Actin (1:50000)(Abcam, Cambridge, MA); 
MyoD (1:500)(Santa Cruz, Dallas, TX). Subsequently, membranes were probed with appropriate 
HRP linked secondary antibodies (1:5000) (Promega, Madison, WI). Protein expression was 
measured using enhanced chemiluminescence reagent (Millipore, Whitby, Ontario) the emitted 
signal was detected using a Kodak In vivo FX Pro and quantified with Carestream molecular 
imaging software (Marketlink Scientific, Burlington, Ontario). 
Cell Cycle Analyses. To determine the cell cycle profiles of RD and Rh30 cells they were 
collected by trypsination, washed twice in cold phosphate buffered saline (PBS), then fixed by 
dropwise addition of ice cold 70% ethanol and stored at -20
o
C for further analyses. Prior to 
sorting, cells were incubated overnight in a staining solution containing PBS, 1 µg/mL 
propidium iodide (PI, Bioshop, Burlington, Ontario) and 0.5µg/mL RNase (Sigma). DNA 
content was measured using Gallios™ flow cytometer (Beckman Instruments, Mississauga, 
Ontario) and cell cycle profiles were determined using ModFit LT 4.0 software (Verity Software 
House, Topsham, ME). 
Statistical Analysis. All statistical analyses were performed using GraphPad Prism 5 
software. Two-way ANOVAs were used to assess the effects of ES and time on protein content. 
Following the correction of protein levels in stimulated cells to reflect variation in control 
conditions one-way ANOVAs followed by Tukey’s post-hoc tests were used to identify 
differences between individual time points. Changes were considered statistically significant 




ES of RD eRMS cells over 5 days resulted in a drastic decrease in cell numbers when 
compared to non-stimulated same day control (CTL) cells. This was accompanied by 
substantially altered cell morphology. ES cells appear larger in size and exhibited a more 
elongated shape after 5 days (Fig. 1A). Cell cycle analysis revealed that ES of RD cells causes a 
statistically significant decrease in the proportion of cells in the G0/G1 population and an 
accumulation during the G2/M when compared to CTL cells. While the amount of cells in S 
phase remained unchanged. After 5 days of ES the G2/M population of RD cells increased by 
30.6% ± 8.25, correspondingly the percentage of cells in G0/G1 decreased by 11.5% ± 4.7 (Fig 
1B, C). This alteration in the cell cycle profiles of ES RD cells is observed as early as day 1, the 
first time point, and last throughout the protocol. 
Despite featuring a different molecular etiology than RD cells, aRMS Rh-30 cells exhibit 
a similar response to ES. On day 4 there are clear distinctions evident with respect to cell 
numbers in ES cells compared to CTL, these Rh-30 cells appear enlarged or detached despite the 
use of gelatin coated culture plates which enhance adhesion (Fig 2A). FACS of Rh-30 cell 
identifies possibly a presence of two distinct populations of cells (Fig 2B). aRMS tumors have 
been shown to often harbour recurrent amplifications or deletion of chromosomal regions (107), 
this could potentially yield the observed shift in the cell cycle profile in a portion of Rh-30 cells. 
Nevertheless, this unusual appearance of FACS outcomes prevented precise cell cycle profile 
determination. Yet, when the number of cells in regions corresponding to the G0/G1 and G2/M in 
each of the populations was estimated a shift from G0/G1 to G2/M following ES in clearly 
identifiable (Fig 2B, C). An observation consistent with the results obtained for RD cells. After 4 
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days of ES one population of cells displays an 80.3% ± 40.05 (p = 0.1) increase in G2/M 
proportion, while the second changed by 64.0% ± 15.23 (p<0.05). 
RMS cells do not arrest in the G1 cell cycle stage following ES. Electrical stimulation of 
C2C12 myoblasts was previously shown to increase the expression of CDK inhibitor protein p27 
and p21 in a AMPK dependent mechanism (93). p27 restricts the activity of Cyclin E/CDK2 
complexes at the G1/S transition which leads to cell cycle arrest and induction of the myogenic 
differentiation program. Unlike the results observed in C2C12 myoblasts, ES does not activate 
AMPK in RD cells as indicated by the phosphorylation levels at T172. pAMPKT
172
 levels are 
decreased in stimulated cells as early as day 1 and remain reduced throughout the protocol (Fig 
3A). Phosphorylation of p27 on T198 increases protein stability and contributes to growth arrest 
and autophagy (95). Moreover, the energy sensor AMPK was shown to directly phosphorylate 
p27 on T198 (95). Electrical stimulation of skeletal myoblasts was previously shown to activate 
AMPK and increase the levels of both p27
T198
 and consequentially total p27 protein (93). In RD 
cells p27
T198
 protein levels on day 1, 2 and 3 while not significantly lower compared to day 0 are 
decreased relative to the value observed on day 5 (Fig S1). Total p27 protein expression is 
decreased in ES RD cells on day 1, however there is variations observed in the levels of this 
protein in the following days possibly implicating other regulatory mechanism. This 
demonstrated that pAMPK, p27, and p27
T198
 are affected differently by electrical stimulation in 
RD cells when compared to C2C12.  Cyclin E was used as another indicator of the G1/S 
transition. ES induced a statistical change in Cyclin E levels over time yet no differences were 
observed between individual days (Fig 3A). Unlike in RD cells, ES activates AMPK in Rh-30 
cells with pAMPK
T172
 levels were determined to be 1.92 ± 0.51 fold above control after 4 days 
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(Fig 3B). The protein levels of p27 were not altered in Rh-30 cells. Similarly, there were no ES-
induced changed in Cyclin E levels in these aRMS cells (Fig 3B). 
Given the decrease in the number of RMS cells after ES we wished to evaluate whether 
this reduction is a result of programmed cell death pathways. FACS analyses showed no 
indication of cells undergoing DNA fragmentation, as evidenced by the lack of a sub-G1 
population (Fig 1A, 2A). To assess the effects of ES on autophagy we measured protein levels of 
two members of the pathways. LC3 is an important regulator of autophagosome maturation. The 
activation of LC3 is critical to the autophagic pathway and it is achieved via the conversion of 
the cytosolic LC3-I into the lipidated, membrane bound LC3-II form. Five days of ES of RD 
cells induced a 2.72 ± 0.37 fold increase in the levels of LC3-II as a fraction of total protein 
content above those in non-stimulated controls (Fig 4A), while in Rh-30 cells the value on day 4 
is 2.29 ± 0.18 relative to day 0 (Fig 4B). Total LC3 protein levels were also measured following 
electrical stimulation. Similar to the outcomes observed for the fraction of activated LC3-II, total 
protein levels increase significantly by day 4 in Rh-30 cells (Fig S2B) and appear to accumulate 
in RD cells (n=2) (Fig S2A). Beclin-1 protein content did not statistically vary between the 
conditions in either cell line.  
Akt activation is enhanced in electrically stimulated RMS cells. In RD cells, ES 
elucidated a 2.21 ± 0.25 fold increase in the abundance of active pAkt
T308
 (Fig 5A). Similarly, ES 
of Rh-30 cells induced a 3.00 ± 1.60 fold increase in pAkt
T308
 above those levels in CTL cells 
(Fig. 5B). Akt plays a role on proliferation and survival but also in myogenic differentiation, and 
the significance of the observed activation of this kinase in ES cells is yet to be fully clarified. To 
further investigate the influence of Akt in RMS cells we used a pharmacological inhibitor of Akt 
activation in conjunction with electrical stimulation. It is evident that Akt inhibition further 
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enhanced cell loss following electrical stimulation in Rh-30 cells (Fig S3). However, it is not yet 
clear what the molecular implications of that are. This result puts forth a notion that despite the 
positive outcomes of enhancing the ability of RMS cells to undergo myogenic differentiation, it 
might instead be more advantageous to strengthen the cell death response induced by electrical 
stimulation in the Rh-30 cells. 
Since RMS tumor cells express MRFs, we measured MyoD and myogenin protein levels 
in RD and Rh-30 cells in order to evaluate the myogenic changes in these cells following ES. 
Myogenin protein levels were drastically decreased in both RD and Rh-30 cells as early as day 1 
and remained supressed for the duration of the protocol. By the final day myogenin content 
decreased 38% ± 12 and 71% ± 7 in RD and Rh-30 cells respectively relative to the value 
observed on day 0 (Fig 5A, B). The expression of the MyoD protein is increased 1.67 ± 0.28 fold 
at day 5 of ES in RD and 2.0 ± 0.25 fold on day 4 in Rh-30 cells (Fig 5A, B). 
The mitochondrion is an organelle implicated in the maintenance of the cellular energy 
status and homeostasis, it is also an important mediator of apoptotic and autophagic pathways 
(27). Increased mitochondrial content in myoblasts is shown to parallel the differentiation 
progress (93). In tumorigenic conditions increasing the mitochondrial content potentially 
increases the likelihood these cancers cells would initiate apoptosis. The major function of this 
organelle network is to produce ATP within the cell it relies on aerobic mechanisms to do so. 
Aggressive tumors are often highly hypoxic, they are reliant on anaerobic glycolysis for ATP 
generation (154). In this light, increased mitochondrial content in RMS cells could indicate a 
shift from cancer promoting conditions to detrimental ones. COXIV (cytochrome c oxidase 
subunit IV) is an often used marker of overall mitochondrial content within a cell. COXIV 
protein levels were shown to increase in electrically stimulated myoblasts (93). In RMS cells 
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besides imposing cell cycle arrest, enhancing myogenic differentiation may also contribute to 
increasing the mitochondrial content as in myoblasts. However, since RMS cells are also 
cancerous increased mitochondrial content might contribute to cell death induction. Yet, 
electrical stimulation of RMS cells did not induce any changes in COXIV protein levels (Fig S4). 
This evidence further corroborates the notion that RMS cells do not behave as myoblasts when 
subjected to electrical stimulation. 
Based on the results obtained following electrical stimulation of the myogenic 
rhabdomyosarcoma cells, which indicate that these cells respond differently from myoblasts, we 
tested the application of this protocol towards non-myogenic PC3 prostate cancer cells. After 5 
days of electrical stimulation there is a drastic decrease in the number of prostate cancer cells 
(Fig S5). This result demonstrates that electrical stimulation does not necessarily relies on 
myogenic properties to induce phenotypical changes. Furthermore, this potentially opens an 
avenue to future applications of this intervention in other cancer types, not limited to the 






 Electrical stimulation induces rapid phenotypical changes in skeletal muscle that mimic 
those seen during adaptation to chronic contractile activity. While myoblasts undergo enhanced 
cell cycle arrest and differentiation in response to ES, we show that RMS cells respond 
differently. This challenges the notions that RMS is truly myogenic in nature. Despite this, ES of 
RMS cells did drastically reduce the number of these cells which is a positive outcome. These 
cells respond in a way distinct from myoblasts but do show signs of arrested proliferation and 
enhanced cell death. This raises the possibility that other non-myogenic cancer cells may respond 
likewise to electrical stimulation. 
ES induces distinct and rapid cell cycle responses in RMS cells with an apparent shift of 
the population from G0/G1 to G2/M. This could be due to a specific arrest of cells in G2/M prior 
to undergoing autophagy and consistent with the lack of G1/S arrest. The observed arrest could 
be due to a number of factors including lack of Cyclin B/CDK1 induction, insufficient Anaphase 
Promoting Complex activity, or deficiencies in the separation of the sister chromatids in mitosis 
(13). Further experiments are required to evaluate the exact nature of this ES-dependent effect. 
Nonetheless, ES is likely to restrict the progress through the cell cycle and help inhibit 
proliferation and induce autophagy, both of these processes contribute to the observed reduction 
in cell numbers. It was previously demonstrated that electromagnetic forces are able to disrupt 
the separation of the sister chromatids during mitosis and cause cell cycle arrest and cell death in 
various cancer cells (155, 156). We show similar effects of ES on RMS cells with further 
evidence of autophagy activation which leads to cell death. Akt is necessary for cell cycle 
progression through the G2/M into the following G1 stage, also kinase activity is enhanced during 
this step and when it was inhibited cell death was prevalent (139, 157, 158). We show that ES 
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promotes Akt activation, as indicated by measuring pAkt
T308
 levels. In contrast, the G2/M 
progression is inhibited. The reasons for this are unclear, but Akt kinase activity may not be 
actually increased in despite the raised levels of pAkt
T308 
in ES RMS cells. Ultimately, the 
increase in pAkt
T308
 may in fact be a response of the cell to prevent the ES-dependent effects 
towards autophagy induction, as Akt mediates the activation of mTOR complex which in turn 
inhibits autophagy (33, 139). Further work needs to be conducted to establish the specific effects 
of Akt activation in RMS cells following ES. 
Deficiencies in the apoptotic pathway and DNA damage response are common in tumors 
(15, 96). p53 is a critical mediator of DNA damage response and is mutated in both RD and Rh-
30 cells (124). This may explain the observed lack of apoptosis in electrically stimulated RMS. 
We show that despite p53 deficiencies ES activated autophagy, giving RMS cells an alternative 
mechanism to induce cell death which represents an attractive target for therapeutic intervention 
(20, 159). Lipidation of LC3 is often used to evaluate the autophagy pathway, as it is an event 
critical to the maturation of the autophagosome (31, 34). The autophagosome in turn fuses with a 
lysosome to degrade the cytoplasmic cargo it contains, while excessive degradation of cellular 
components leads to cell death (31, 33). Leading up to the conversion of LC3-I into LC3-II, the 
Beclin 1 complexes must be activated (33). Beclin 1 insufficiency contributes to the development 
of some cancers (160), yet it is also extensively regulated at the protein level through post-
transcriptional modification as well as protein-protein interactions (33). Also, Beclin 1 contains a 
BH3-only domain and the activity of this protein is inhibited through the binding of the anti-
apoptotic Bcl-2 factors (33). This mechanism may permit Akt mediated intervention in Beclin 1 
activation. Akt phosphorylates and inhibits the pro-apoptotic BAD factor which binds and 
sequesters the anti-apoptotic Bcl-2 protein, thus preventing it’s the downstream effects (29, 139). 
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This may explain why we observed ES-induced changes in LC3 yet no effects on Beclin 1. With 
Akt being activated in response to ES in RMS cells, this may have prevented the induction of 
Beclin 1 with no inhibitory effects on LC3. This allowed cell death to proceed as indicated by the 
observed decrease in RMS cell numbers following ES. This result may also suggest the LC3 
plays a more critical role in autophagy activation than Beclin 1.  
The expression of factors essential for myogenesis is a well-documented feature of RMS, 
yet the contribution of the myogenic regulators to the manifestation of this cancer type remains 
undefined. The MRF myogenin regulates the expression of genes necessary for the late stages of 
differentiation and myoblast fusion (44). RMS tumors express myogenin, however its 
transcriptional activity was shown to be inhibited in PAX3/FOXO positive cells as a results of a 
direct phosphorylation by GSK3β (140). ES-induced activation of Akt inhibits GSK3β, 
alleviating its suppressive effects on myogenin and consequentially increasing its transcriptional 
activity, and decreasing proliferation in aRMS Rh-30 cells (140). Furthermore, PAX3 
transcriptional activity is known to inhibit differentiation in myoblast (49, 57). Given that aRMS 
cells express a constitutively active chimeric protein this may also be occurring in aRMS cells. 
The FOXO protein is phosphorylated by Akt which leads to its inactivation by translocation out 
of the nucleus (143). The regulatory domain of FOXO is part of the PAX/FOXO chimeric 
protein and was initially thought to be unresponsive to Akt-dependent regulation because it only 
possesses 2 out of the 3 phosphorylation sites (143). However, it was recently demonstrated that 
Akt does in fact modulate the activity of PAX/FOXO (144, 145), since ES promotes Akt 
activation in Rh-30 cells it might serve as a potential therapeutic intervention (144, 145). As 
opposed to Akt mediated inhibition of cell death pathways which would enhance survival, ES 
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mediated effects towards myogenin and PAX/FOXO in aRMS cells further prevent proliferation 
and invasiveness. 
Given our results it appears that ES of RMS represents a potential novel therapy. ES 
induces G2/M arrest which is accompanied by cell death via autophagy. Concomitant activation 
of Akt further reduces the proliferation of Rh-30 cells by inhibiting GSK3β which represses 
myogenin transcriptional activity. Moreover, ES may only affect proliferating cells as shown 





7.6. Figure Legends 
Figure 1. Electrical stimulation of RD cells induces cell cycle changes. Stimulation (ES) 
of RD cells over 5 days progressively decreased cell numbers, altered cell morphology (A) and 
caused an accumulation of cells in the G2/M phase of the cell cycle (B) compared to non-
stimulated control (CTL) RD cells. (C) Graphical summary of the percentages of cells in each 
phase of the cell cycle in response to 1, 3 and 5 days of ES.  All values are mean ± S.E.M.; 
*p<0.05 compared to same day CTL (n=4). 
Figure 2. Electrical stimulation of Rh-30 cells induces cell cycle changes. Following 2 or 
4 days of electrical stimulation (ES) Rh-30 cells display decreased cell numbers and altered cell 
morphology compared to non-stimulated control (CTL) cells (A). FACS profiles of Rh-30 cells 
indicate a shift towards G2/M in response to ES (B, C). All values are mean ± S.E.M.; *p<0.05 
compared to same day CTL (n=3-5). 
Figure 3. Electrical stimulation affects AMPK, p27 and Cyclin E in RMS cells. Electrical 
stimulation (ES) decreases pAMPK
T172 
protein levels in RD cells while concomitantly 
decreasing p27 and increasing Cyclin E protein levels (A). ES increased pAMPK
T172
 protein 
levels in Rh-30 cells but no ES induced changes in protein levels of p27 and Cyclin E were 
observed (B). β-actin was used to correct for protein loading. Proteins in stimulated cells (S) 
were quantified relative to those in non-stimulated control (C) cells.  All values are mean ± 
S.E.M.; *p<0.05 compared to Day 0; **p<0.05 main effect of one-way AVOVA (n=5). 
Figure 4. Electrical stimulation activates autophagy in RMS cells. ES leads to conversion 
of LC3-I (upper arrow) into the active LC3-II (lower arrow) in both RD (A) and Rh-30 (B) cells. 
Protein levels of Beclin 1, another autophagy mediator, remained unchanged by ES (A, B). β-
actin was used to correct for protein loading. Proteins in stimulated cells (S) were quantified 
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relative to those in non-stimulated control (C) cells. All values are expressed as mean ± S.E.M. 
*p<0.05 compared to Day 0 (n=3-5). 
Figure 5. Electrical stimulation of RMS cells activates Akt and affects myogenic 
regulatory factors. ES activates Akt (pAkt
T308
) in RD cells (A). In addition ES decreased 
myogenin and increased MyoD in RD cells (A). Similar responses to ES were observed in Rh-30 
cells (B). β-actin was used to correct for protein loading. Proteins in stimulated cells (S) were 
quantified relative to those in non-stimulated control (C) cells. All values are expressed as mean 
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 is a direct phosphorylation target of pAMPK, following this post-
transcriptional modification  protein stability is increased. β-actin was used to correct for protein 
loading. Proteins in stimulated cells (S) were quantified relative to those in non-stimulated 
control (C) cells. All values are expressed as mean ± S.E.M. *p<0.05 compared to Day 0, 







Figure S2. Total LC3 protein levels in electrically stimulated RD (A) and Rh 30 (B) cells. β-actin 
was used to correct for protein loading. Proteins in stimulated cells (S) were quantified relative to 
those in non-stimulated control (C) cells. All values are expressed as mean ± S.E.M. *p<0.05 












Figure S3. Rh-30 cells following 4 days of electrical stimulation or control condition with and 
without pharmacological Akt inhibition. Cells were treated with 10 µM of 1L6-Hydroxymethyl-
chiro-inositol-2-(R)-2-O-methyl-3-O-octadecyl-sn-glycerocarbonate a commercially available, 
specific inhibitor of Akt activation. The drug prevents binding of the Akt protein to its upstream 
activator via competitive interaction. Dimethyl sulfoxide (DMSO) was used as vehicle control. 
























Figure S4. COXIV was measured to help reflect on the changes in the mitochondrial content in 
electrically stimulated cells. β-actin was used to correct for protein loading. Proteins in 
stimulated cells (S) were quantified relative to those in non-stimulated control (C) cells. All 
values are expressed as mean ± S.E.M. *p<0.05 compared to Day 0, n=5 in RD (A) and  n=3 in 






















Figure S5. PC3 cells, a non-myogenic prostate cancer cell line, following 5 days of electrical 














The nature of RMS tumors as both oncogenic and myogenic offers a unique opportunity 
to capitalize on the knowledge of muscle biology and apply it in a cancer context. Cancer is a 
disease that most often presents itself in the aged population and is frequently classified on the 
basis of the tissue it originates from. RMS tumors are statistically rare and they manifest 
themselves during childhood and adolescence and in a variety of locations. However, at the 
molecular level most cancers, including RMS, exhibit some common set of molecular 
determinants which shape the malignancy. Unlike other cancer forms RMS tumors express a 
range of factors implicated in the myogenic differentiation program. While, myogenesis is a 
popular research field and numerous approaches exist to intervene in the molecular mechanisms 
which regulate this process, few are applied to RMS. The differentiation program is deficient in 
RMS cells and the potential of therapeutic strategies aimed towards myogenic regulators is 
questionable. In this thesis the use of the electrical stimulation on RMS cells was evaluated, as 
previously it was shown to induce cell cycle arrest and differentiation in myoblasts.  
Electrical stimulation induces arrest of proliferation and cell death in both subtypes of 
RMS, it also leads to obvious morphological changes. However, the alterations observed in RMS 
cells following electrical stimulation are unlike the ones observed in myoblasts. In myoblasts 
electrical stimulation induces cell cycle arrest likely at the G1/S transition mediated by an 
increase in p27 protein levels and decrease in Cyclin E. In RMS cells such changes were not 
induced by electrical stimulation, and in agreement cell cycle profiling indicated no build up in 
G1/S but instead there was an accumulation of cells in the G2/M phase. It is unclear at this point 
which molecular mechanisms mediate this cell cycle alteration, nor whether the cells arrest at the 
G2/M transition or during M phase.  
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Programmed cell death pathways can be initiated in response to cell damage and repair 
must take place in a timely manner to ensure survival. This fact is utilized in many cancer 
therapies as the induction of massive DNA damage in tumors can lead to induction of cell death 
pathways and destruction of tumor cells. However, the regulators of cell death pathways are 
often deficient in cancers. p53 is an important regulators of cellular responses to stress and it is 
often mutated in RMS, including RD and Rh-30 cell lines. Both apoptosis and autophagy were 
evaluated in electrically stimulated RMS cells as these cell death modes could potentially 
contribute to the cell loss elicited by electrical stimulation. At this point it is unclear if cell cycle 
precedes cell death in electrically stimulated RMS cells. The G2/M accumulation was observed at 
the earliest time point of electrical stimulation in both cell lines studied, yet signs of apoptotic 
cell death were not detected. However, the autophagy pathways protein LC3 was activated by 
day 4 in both RD and Rh-30 cells. Nevertheless, both cell cycle arrest and cell death are 
implicated in the apparent decrease in RMS cell numbers following electrical stimulation.  
The Akt pathway fulfills a diverse range of roles important for cellular functions with 
some individual effects having conflicting implications in RMS cells. In cancer cells excessive 
Akt activation is often observed and it contributes to proliferation and evasion of cell death. 
Conversely, in myogenesis Akt is required for differentiation to take place. In an earlier study we 
report that myogenin transcriptional activity is prevented through the influence of GSK3β in 
PAX3/FOXO positive aRMS cells. Inhibition of GSK3β alleviated the suppression of myogenic 
gene expression and decreased both proliferation and survival of Rh-30 cells (140). We 
demonstrated that electrical stimulation induces Akt activity, inhibits GSK3β, and activates the 
expression of myogenin targets (140). Separately, Akt activity towards the PAX/FOXO fusion 
gene was shown to inhibit growth and invasiveness while also inducing cell death in aRMS cells 
67
(144, 145), a process likely rooted in the myogenic traits of these cells. In conventional tumor 
cells Akt signalling promotes proliferation and survival, however since RMS possess myogenic 
properties, Akt also mediates effects with contribute to enhanced differentiation, growth arrest 
and cell death.  Thus, Akt actions in this myogenic context are in direct conflict with its pro 
survival function, and it is not clear which option is more advantageous in preventing the growth 
of RMS tumors if this kinase was to be targeted through a pharmacological approach. Electrical 
stimulation on the other hand likely acts through numerous mechanisms as changes in cell cycle, 
survival and myogenic status all take place in conjunction with Akt activation. The relative 
effectiveness of the contribution of Akt mediated changes in myogenic status to the overall 
phenotype observed in electrically stimulated Rh-30 cells is yet to be determined. However, 
preliminary evidence suggests that pharmacological inhibition of Akt coupled with electrical 
stimulation might further enhance the degree of cell loss. Inhibition of GSK3 was recently shown 
to lead to cell death in eRMS cells as well (141). However, neither GSK3 analyses nor Akt 
inhibition are have been completed in RD cells following electrical stimulation. 
The fact the RD and Rh-30 cell do not exhibit a response comparable to the one observed 
previously in C2C12 myoblasts questions the merit of treating RMS cells as myogenic. 
However, the nature of the response and the fact it is unlike the one elicited in myoblasts puts 
forth an interesting possibility that other non-myogenic cancer cells could respond in a manner 
similar to RMS cells when subjected to electrical stimulation. To test this possibility we 
electrically stimulated a non-myogenic prostate cancer PC3 cell line and the preliminary 
evidence points to a decrease in the number of cells after 5 days of this treatment. Further 
experiments are required to elaborate on this line of evidence as it might carry significant 
implications on cancer therapeutic approaches.  
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9. Limitations and Future Directions 
Evidence obtained so far, taken together with the main hypotheses of this thesis, help 
identify a number of prospective areas that need to be further investigated. Other areas could also 
be addressed to help strengthen the validity of the collected data. In-vitro application of the 
electrical stimulation model proved promising but not without its out challenges. Ultimately 
while the outcomes observed in-vitro provide an exciting opportunity to investigate the 
molecular properties of RMS cells, the potential of electrical stimulation as a therapeutic 
intervention will depend of whether or not it can be successfully and effectively applied in-vivo. 
Moreover, in light of the results obtained to date it is important to test whether the effects 
electrical stimulation on RMS cells could also be consistently replicated in other non-myogenic 
cancer cell lines or if they are unique to RMS. It is also imperative to establish a baseline through 
the use of non-cancerous yet dividing cells, besides the aforementioned myoblasts.  
Even though the loss of RMS cells following electrical stimulation is clear and both cell 
cycle arrest and cell death appear to be implicated, further experiments are required to strengthen 
our grasp of these events. Originally it was hypothesized that the G1/S transition will be 
prevented following stimulation if the myogenic RMS cells behave similar to myoblasts, this was 
not the case. An immunoprecipitation of Cyclin E bound p27 in combination with p27 cellular 
localization assays would add to the strength of the conclusion that could be made about this cell 
cycle stage. FACS results strongly suggest a G2/M accumulation of cells following stimulation, 
yet it is not clear what molecular mechanisms are responsible for that. Cyclin B/CDK1 and APC 
activity, as well as the mitotic spindle assembly process could all be assessed to further evaluate 
the nature of the observed G2/M arrest. Also, it might be important to distinguish if the cells 
arrest at the G2/M transition or during Mitosis. Nevertheless, p27 does also inhibit the Cyclin 
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B/CDK1 complexes which regulate the transition stage. The inability to detect the p27
T198
 in Rh-
30 cells, and the other important CDK inhibitor p21 in both RMS cell lines, leave gaps in our 
understanding of the mechanism responsible for the cell cycle effects of electrical stimulation. 
Electrical stimulation of RMS cells causes the activation of Akt signalling. While the 
activity of this kinase is believed to prevent cell death and contribute to cell cycle progression, it 
may also serve a different role in myogenic and Rh-30 cells by promoting differentiation. 
Pharmacological inhibition of Akt may further decrease the number of cells remaining following 
electrical stimulation. The full consequences of Akt inhibition in Rh-30 cells, as well as in the 
RD line, are yet to be determined. It is important to further establish that by combining 
stimulation and pharmacological inhibition of Akt activation. Furthermore, recent evidence 
points to the contributions of calcium signalling to Akt activity and apoptosis in aRMS cells 
(145). Chelation of calcium out of electrically stimulated myoblasts attenuated cells cycle arrest 
(93). Together, these observations put forward a notion that calcium signalling could act as the 
mediator of the responses RMS cells exhibit following electrical stimulation. However, further 
research is required to establish the possibility of such connection. At this stage it is not clear 
what mechanisms contribute to the activation of the Akt pathway. Often this kinase is activated 
downstream of the growth factor mediated receptors, yet this is not the case in electrically 
stimulated RMS cells. 
GSK3β activity is important to the manifestation of the tumorigenic state in PAX/FOXO 
positive cells. As we demonstrate Akt mediated inhibition of GSK3β in Rh-30 cells helps 
alleviate the suppression of myogenin transcriptional activity. Changes in E box driven promoter 
reported activity was used to help assess myogenic differentiation status. Yet, these experiments 
could be revisited to offer a more comprehensive outlook on the myogenic changes occurring in 
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these cells. While after 2 days of electrical stimulation E box driven luciferase expression was 
statistically increased, the full length MCK promoter activity did not show any changes. To 
expand our understanding measurements of myogenic gene expression in electrically stimulated 
aRMS cells at additional time points including day 0 and day 4 should be conducted. Moreover, 
the enhanced activation of the E box but not the full length MCK promoter driven reporter gene 
expression implicates the participation of other transcriptional regulators that impose the 
differentiation block in aRMS. Finally, E box activation is not exclusively targeted by myogenin, 
it is also mediated by other MRFs such as MyoD. MyoD mediated transcriptional activity was 
not addressed in this project, yet taking into account the significant increase in the protein levels 
of this factor in electrically stimulated Rh-30 cells, it could serve as a potential topic for further 
research. Moreover, recently GSK3 was also shown to support the oncogenic state in eRMS 
cells, yet it is unclear how electrically stimulated RD cells respond to changes in this kinase. It is 
possible the myogenic program in eRMS cells is influenced similarly to Rh-30 cells in terms of 
GSK3 effects towards myogenic differentiation. Thus, it could provide an exciting opportunity to 
expand our understanding of the myogenic state in eRMS cells as well. 
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Glycogen synthase kinase 3b represses MYOGENIN
function in alveolar rhabdomyosarcoma
MG Dionyssiou1, S Ehyai1, E Avrutin2, MK Connor2 and JC McDermott*,1,3,4,5
MYOGENIN is a member of the muscle regulatory factor family that orchestrates an obligatory step in myogenesis,
the terminal differentiation of skeletal muscle cells. A paradoxical feature of alveolar rhabdomyosarcoma (ARMS),
a prevalent soft tissue sarcoma in children arising from cells with a myogenic phenotype, is the inability of these cells to
undergo terminal differentiation despite the expression of MYOGENIN. The chimeric PAX3-FOXO1 fusion protein
which results from a chromosomal translocation in ARMS has been implicated in blocking cell cycle arrest, preventing
myogenesis from occurring. We report here that PAX3-FOXO1 enhances glycogen synthase kinase 3b (GSK3b) activity which
in turn represses MYOGENIN activity. MYOGENIN is a GSK3b substrate in vitro on the basis of in vitro kinase assays and
MYOGENIN is phosphorylated in ARMS-derived RH30 cells. Constitutively active GSK3b(S9A) increased the level of a
phosphorylated form of MYOGENIN on the basis of western blot analysis and this effect was reversed by neutralization of the
single consensus GSK3b phosphoacceptor site by mutation (S160/164A). Congruently, GSK3b inhibited the trans-activation of
an E-box reporter gene by wild-type MYOGENIN, but not MYOGENIN with the S160/164A mutations. Functionally,
GSK3b repressed muscle creatine kinase (MCK) promoter activity, an effect which was reversed by the S160/164A mutated
MYOGENIN. Importantly, GSK3b inhibition or exogenous expression of the S160/164A mutated MYOGENIN in ARMS reduced
the anchorage independent growth of RH30 cells in colony-formation assays. Thus, sustained GSK3b activity represses a critical
regulatory step in the myogenic cascade, contributing to the undifferentiated, proliferative phenotype in alveolar
rhabdomyosarcoma (ARMS).
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Rhabdomyosarcoma (RMS) is the most common pediatric
soft tissue sarcoma, accounting for 5% of all childhood
cancers and approximately 50% of soft tissue sarcomas.1–3
There are two main subtypes: embryonal and alveolar RMS
and although embryonal RMS is more common, alveolar RMS
is considered to carry a worse prognosis. A gene fusion
resulting in the t(2;13)(q35;q14) somatic cell chromosomal
translocation fuses PAX3 and Foxo1 to create a potent
transcription factor (PAX3-FOXO1) which is a predominant
causative genetic lesion for the development of alveolar
rhabdomyosarcoma (ARMS).1 ARMS is a highly malignant
mesenchymal tumor that has properties of immature striated
muscle tissue resulting in dense aggregates of poorly
differentiated cells that are separated by fibrous membranes
resulting in a loss in cellular cohesion.2,3 PAX3 is a key
determinant of somatic myogenesis and, is involved in the
migration of progenitor cells to the dermomyotome region of
the somite where they grow and divide in the presence of
growth factors.4 PAX3 is also required to activate the
myogenic determination gene, MYOD.5 MYOD is one of four
myogenic regulatory factors (MRFs, which include MYF-5,
MRF4 and MYOGENIN) from the basic helix-loop-helix
superfamily of transcription factors which interact with
myocyte enhancer factor-2 (MEF2) proteins in the hierarchical
control of muscle-specific gene expression.6 Two kinases that
potently exert effects on this myogenic regulatory cascade are
p38 mitogen activated protein kinase (MAPK) and glycogen
synthase kinase 3b (GSK3b). p38 MAPK is a key regulator of
skeletal myogenesis that critically interacts with and activates
MEF2 in the somite myotome during development.7–9 Con-
versely, GSK3b activation leads to a repression in skeletal
and cardiac muscle differentiation, in part by antagonizing p38
MAPK-mediated activation of MEF2.10,11 GSK3b usually
targets proteins that have already been phosphorylated by
another kinase at a ‘priming’ serine or threonine residue
located four amino acids C-terminal to a consensus
(S/T)XXX(S/T)-PO4 motif.
12,13 Regulation of MEF2 and the
MRFs leads to morphological changes including epithelial to
mesenchymal transition, cell alignment and fusion to form
multinucleated myotubes that eventually develop into
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functional, contractile muscle fibers. In particular, cells that
express MYOD and MYOGENIN are typically fusion compe-
tent14,15 with the exception of ARMS cell types. To date, lack
of myogenic differentiation of PAX3-FOXO1 expressing
ARMS cells has been attributed to their inability to upregulate
p57Kip2 activity, hence destabilizing the DNA binding affinity of
MYOD transcription complexes.16 Dysfunctional MYOD/E-
protein complex association and transcriptional control is a
common feature between ARMS and the non-PAX3-FOXO1
expressing embryonal rhabdomyosarcoma (ERMS). Sub-
sequent restoration of the MYOD/E12 complex has been
shown to switch ERMS cells from an arrested myofibroblast
phase to a more differentiated state.17 Similarly p38 MAPK
activity can potentiate myogenic differentiation in ERMS cells
by enhancing MYOD trans-activation properties.18 Therefore,
it is fairly clear that in both rhabdomyosarcoma subtypes the
ability of MYOD to potentiate transcription is compromised.
However, the role of MYOGENIN in RMS is more equivocal.
For normal myogenesis to occur, both in vitro and in vivo, an
absolute requirement for MYOGENIN is evident. Thus,
MYOGENIN activity constitutes a pivot point for irreversible
commitment to terminal differentiation.19,20 The combination
of data from gene targeting studies of the MRFs21,22 supports
the prevailing consensus that while the other three MRFs can
compensate each other’s functional roles,23–26 MYOGENIN is
absolutely essential for skeletal muscle fiber formation.20
Despite its expression in RMS, the paradox as to why
MYOGENIN cannot mediate competence for differentiation
is unknown.
Here, we examined the posttranslational regulation of
MYOGENIN in ARMS. On the basis of the in silico prediction
of a single consensus phosphorylation site for GSK3b on the
MYOGENIN protein and also high levels of GSK3b activity in
these cells, we determined that MYOGENIN function is
potently repressed by GSK3b activity in ARMS. Moreover,
pharmacological inhibition of GSK3b results in a profound
decrease in size and, to a certain extent, number of RMS
colonies in a colony-formation assay. This effect is mimicked
by introduction of MYOGENIN bearing neutralizing mutations
in the GSK3b consensus site. In combination, these data
reveal MYOGENIN as a key target of GSK3b activity in
Cell Type RH30 C2C12
Condition DM







































Figure 1 MYOGENIN protein expression and GSK3b activity are both
maintained in ARMS: (a) C2C12 myoblasts were transfected with HA-PAX3-
FOXO1 or pcDNA3.1 control plasmid for 1 day before extraction or serum
withdrawal and then extraction at 1 day increments for up to 4 days as indicated.
Protein levels were compared with protein extracts from PAX3-FOXO1 expressing
RH30 cells 1 day in growth media (GM) and 4 days in differentiation media (DM).
The results show that despite the expression of PAX3-FOXO1, RH30 cells also
express MYOGENIN. On the other hand, HA-PAX3-FOXO1 overexpression in
C2C12 inhibits MYOGENIN expression and subsequent myogenic differentiation.
(b) C2C12 myoblasts were transfected with CMV-dsRed2, MCK-eGFP and, either
HA-PAX3-FOXO1 or pcDNA3.1 control plasmid. HA-PAX3-FOXO1 overexpression
repressed the formation of multinucleated myotubes. (c) Endogenous GSK3b
protein levels and phosphorylation at serine 9 were compared in C2C12 myoblasts,
RH30 and ERMS RD cells. Although GSK3b is expressed in all three cell types, it is
predominantly phosphorylated and hence inactive in C2C12 myoblasts and RD cells
but not PAX3-FOXO1 expressing RH30 cells. (d) C2C12 myoblasts were
transfected with HA-PAX3-FOXO1 or pcDNA3.1 control plasmid for 1 day before
extraction. Overexpression of HA-PAX3-FOXO1 resulted in decreased phospho-
rylation of GSK3b at serine 9 indicating its activation
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ARMS, indicating that pharmacologic manipulation of this
signaling axis may provide an opportunity for therapeutic
intervention.
Results
MYOGENIN is expressed in PAX3-FOXO1 expressing
RH30 cells. Serum (10% FBS) contains growth factors that
repress the transcriptional activity of MRFs and also
stimulate cell cycle progression hence rendering C2C12
myoblasts proliferative. In tissue culture, serum withdrawal
(2% HS) results in activation of MEF2 and MRFs causing cell
alignment and fusion to form multinucleated myotubes.
Initially, in order to investigate the effect of PAX3-FOXO1
on this differentiation program, proliferating C2C12
myoblasts were transiently transfected with CMV-dsRed2,
MCK-eGFP, and either HA-PAX3-FOXO1 or pcDNA3.1
control vector. Growth media (GM) was replaced with
differentiation media (DM) 19 h after transfection and cells
were allowed to differentiate for 96 h. SDS-PAGE samples
were prepared from populations of myoblasts that either
expressed or did not express PAX3-FOXO1, (a) before
serum withdrawal (time¼ 0; GM¼ 10% FBS) and (b) at 24 h
increments upon serum withdrawal (days 1–4; DM¼ 2% HS).
Protein expression levels of these samples were then
compared with protein samples from PAX3-FOXO1 expres-
sing RH30 cells in GM and DM, by western blotting. These
data indicate that despite the expression of PAX3-FOXO1,
MYOGENIN protein expression is maintained in human
ARMS-derived RH30 cells (Figure 1a). In addition, PAX3-
FOXO1 repressed myotube formation in C2C12 myoblasts
(Figures 1a and b). Detection of myogenic differentiation
using an MCK promoter driving GFP expression27 revealed
GFP expressing, multinucleated myotubes in the controls but
not in cells expressing PAX3-FOXO1 (Figure 1b).
It is well documented that MRFs and MEF2 proteins are
highly sensitive to pro-myogenic kinases such as p38
















































Figure 2 Overexpressed, constitutively active GSK3b (S9A) represses MYOGENIN trans-activation of E-box. (a) C2C12 myoblasts were transfected with 4x E-box Luc
reporter and different combinations of HA-GSK3b(S9A) and MYOGENIN or pcDNA3.1 control plasmid as indicated. Overexpressed HA-GSK3b(S9A) repressed MYOGENIN
transcriptional activity (Po0.001). (b) GSK3b directly phosphorylates MYOGENIN in vitro: Purified GST-MYOGENIN was incubated in vitro with GST-GSK3b and (g-32P) ATP.
GST and MBP proteins were used as negative and positive control respectively as indicated. Bands were resolved using SDS-PAGE and visualized by Coomassie Blue staining.
Gels were dried and exposed to X-ray film for 21 h after the assay. (c) Calf-intestinal phosphatase (CIP) treatment of immunoprecipitated MYOGENIN that was obtained from
1000mg of RH30 protein extract. The data shows that CIP treatment causes a loss of a high-molecular weight, phosphorylated form of MYOGENIN. #ns, ***Po0.001
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repressive to myogenesis.10,31 Therefore we tested for
GSK3b activity under conditions when myogenesis is
supressed. As GSK3b is constitutively active until it is
repressed by phosphorylation at serine 9 (by PKB), we
assessed both total GSK3b protein expression levels and S9
phosphorylation levels using appropriate antibodies as
indicated. We document that GSK3b is expressed in
proliferative C2C12 myoblasts, PAX3-FOXO1 expressing
ARMS cells (RH30) and, non-PAX3-FOXO1 ERMS cells
(RD). However only in PAX3-FOXO1 expressing RH30 cells,
is GSK3b predominantly in its unphosphorylated form (at
serine 9) and, hence fully active state (Figure 1c). In addition,
ectopic expression of PAX3-FOXO1 resulted in reduced
phosphorylation of GSK3b at serine 9 in C2C12 myoblasts
(Figure 1d).
MYOGENIN trans-activation function is repressed by
GSK3b. To assess the effect of GSK3b activity on MYO-
GENIN function, trans-activation of a 4x E-box Luciferase
construct was measured in proliferating C2C12 myoblasts
that were transfected with different combinations of consti-
tutively active GSK3b(S9A) and MYOGENIN as indicated in
Figure 2a. The data indicate that MYOGENIN potentiates the
4x E-box Luc reporter gene and that GSK3b(S9A) abrogates
this effect (Po0.001) indicating repression of MYOGENIN by
active GSK3b (Figure 2a, left panel) without affecting the
MYOGENIN protein expression levels (Figure 2a, right
panel).
GSK3b directly phosphorylates MYOGENIN in vitro. In
order to determine whether MYOGENIN is a substrate for
GSK3b, an in vitro kinase assay was performed using GST-
MYOGENIN (1–225), purified GST-GSK3b and g-32P ATP.
Bands were resolved using SDS-PAGE and subsequent
autoradiography showed 32P labeled bands for MYOGENIN,
autophosphorylated GSK3b and MyBP (positive control,
Figure 2b). In addition, Coomassie Blue staining revealed a
lower mobility band indicative of phosphorylation (Figure 2b).
To further test the idea that the lower mobility band is
hyperphosphorylated, we used calf-intestinal phosphatases
on RH30 cell lysates and found that the low mobility band
was eradicated (Figure 2c). Collectively these data suggest
that MYOGENIN is a GSK3b substrate in vitro.
Pharmacologic manipulation of GSK3b activity alters
MYOGENIN properties. To further investigate the effect of
GSK3b on MYOGENIN, COS7 cells were co-transfected with
MYOGENIN and GSK3b(S9A) and, then treated with or
without 10 mM GSK3b inhibitor, AR-A014418, as indicated in
Figures 3a and b. Western blot analysis revealed two
predominant forms of MYOGENIN, a low mobility hyper-
phosphorylated isoform and a high mobility, hypophosphory-
lated isoform (Figure 3a, lane 2). The lower mobility,
hyperphosphorylated band is reduced upon pharmacological
treatment with AR-A014418 as indicated (Figure 3a, lane 3).
This corresponded with a significant increase in trans-
activation of an E-box cis element driven reporter gene
(Po0.001, Figure 3b). In contrast, constitutively active
GSK3b(S9A) without pharmacological inhibition resulted in
an increase in the low mobility, hyperphosphorylated band
(Figure 3a, lane 4) which corresponded to a decrease in
E-box luciferase activity in reporter gene assays (Po0.05,
Figure 3b).
Mutation of a consensus GSK3b phosphoacceptor site
on MYOGENIN (S160/164A) prevents GSK3b-mediated
repression. By in silico analysis, MYOGENIN contains a
highly conserved putative GSK3b consensus phospho-
acceptor site (Table 1), which we targeted by neutralizing
site-directed mutagenesis. We observed that although
wild-type MYOGENIN is sensitive to the repressive













































Figure 3 GSK3b increases MYOGENIN protein, possibly through phosphor-
ylation and this corresponds with decreased transcriptional activity. (a) Cos7 cells
were transiently transfected with or without MYOGENIN and/or GSK3b(S9A) and
then treated for 19 h with either 10mM GSK3b inhibitor or DMSO 24 h after
transfection as indicated. Protein samples were extracted and western blot analysis
revealed an increase in a slower migrating, hyperphosphorylated MYOGENIN band
(lane 4) in the presence of overexpressed HA-GSK3b(S9A), which was reduced in
the presence of GSK3b inhibitor (lane 3). (b) E-box Luc reporter gene was
co-transfected in Cos7 cells using the same conditions that were described above.
Overexpressed MYOGENIN significantly enhanced transcriptional activity of the
E-box promoter (***Po0.001) and, this effect was further increased in the presence
of GSK3b inhibitor despite overexpression of GSK3b(S9A) (Po0.001).
Overexpression of GSK3b(S9A) repressed MYOGENIN transcriptional activity
(**Po0.05)
Table 1 GSK3b consensus sequence within Myogenin
Myogenin sequence: Species:
158 VPSECSSHSASCSP 171 Human
158 VPSECNSHSASCSP 171 Mouse
158 VPSECNSHSASCSP 171 Rat
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(S160/164A) was not (Figure 4a). Western blot analysis
revealed that MYOGENIN (S160/164A) mutations corre-
spond with a decrease in the low mobility, hyper-
phosphorylated upper band (Figure 4b, lane 2) and that
this effect was not altered by ectopically expressed HA-
GSK3b(S9A). Together these data indicate that S160/164A
mutations in MYOGENIN render it insensitive to the
repressive effect of GSK3b. GSK3b(S9A) expression
resulted in an increase in the low mobility, hyper-
phosphorylated form of wild-type MYOGENIN (Figure 4b,
lane 3) and this corresponded with decreased E-box luciferase
activity (Po0.001, Figure 4a). Although trans-activation of the
skeletal muscle gene E-box cis-element by mutated MYO-
GENIN (S160/164A) is marginally less potent than wild-type
MYOGENIN (Po0.05, Figure 4c); it is resistant to inhibition
by activated GSK3b (Po0.001, Figure 4c).
PAX3-FOXO1 activation of GSK3b antagonizes muscle
creatine kinase promoter activation. To further examine
the functional significance of our findings, we used MCK
promoter activity, as a key indicator of the activation of
myogenic differentiation, in C2C12 myoblasts that were
transfected with or without the PAX3-FOXO1 oncogene
(Figure 5a). These data depict that PAX3-FOXO1 represses
MCK promoter activation in myoblasts that have been
co-transfected with MYOGENIN (Po0.01) and this effect is
not only abrogated by pharmacological inhibition of GSK3b,
but further activated (Po0.001, Figure 5a). Interestingly, in
PAX3-FOXO1 expressing, human ARMS-derived RH30
cells, ectopically expressed MYOGENIN had no effect on
MCK promoter activity unless it was coupled with pharma-
cological inhibition of GSK3b using AR-A014418 (Po0.001,
Figure 5b). Conversely, mutated MYOGENIN (S160/164A)
Myogenin
Myogenin





























































pGL3 4x E-box -Luc
Figure 4 MYOGENIN neutralizing phosphomutant (S160/164A) is resistant to GSK3b repression of transcription activity as well as an increased slower migrating,
hyperphosphorylated MYOGENIN band. (a) 4x E-box Luc activity was assessed in C2C12 myoblasts that were transfected with either wild-type MYOGENIN or MYOGENIN
(S160/164A) and, co-transfected with HA-GSK3b(S9A) or pcDNA3.1 control plasmid as indicated. HA-GSK3b(S9A) repressed MYOGENIN trans-activation of the 4x E-box
promoter region (Po0.001) but had no effect on mutated MYOGENIN (S160/164A) transcriptional activity. (b) Western blot analysis of the same samples revealed a decrease
in a slower migrating, hyperphosphorylated band for overexpressed MYOGENIN (S160/164A, lane 2) with respect to overexpressed wild-type MYOGENIN (lane 1).
Co-transfected HA-GSK3b(S9A) caused an increase in the slow migrating, hyperphosphorylated MYOGENIN band (lane 3) but not with overexpressed mutated MYOGENIN
(S160/164A, lane 4). (c) Independent analysis of E-box Luc activity in C2C12 myoblasts with different combinations of overexpressed MYOGENIN, mutated MYOGENIN
(S160/164A), HA-GSK3b(S9A) or pcDNA3.1 control plasmid as indicated. ***Po0.001, **Po0.05, #ns
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was able to potentiate MCK promoter activity regardless of
GSK3b inhibition (Po0.05, Figure 5b). Taken together, these
data provide evidence that S160/164 on MYOGENIN are
likely key targets of GSK3b signaling in alveolar rhabdo-
myosarcoma resulting in a diminution of the critical E-box
dependent gene activation that is necessary and sufficient for
differentiation.
Manipulation of GSK3b and MYOGENIN activity reduces
tumorigenic properties of ARMS-derived RH30 cells.
Colony-formation assays were performed as previously
described using RH30 cells32 which can grow in an
anchorage independent manner. Equal numbers of RH30
cells that have been transiently transfected with or without
MYOGENIN containing the S160/164A mutations were
seeded in growth media with or without 10 mM AR-A014418
(GSK3b inhibitor) and allowed to form colonies for 21 days
(Figure 6). The addition of 10 mM AR-A014418 significantly
impaired the ability of RH30 cells to form colonies
(Po0.05) and remarkably reduced the size of the colonies
(Po0.0001). A similar reduction in colony numbers and size
were also evident in RH30 cells that were transfected with
MYOGENIN (S160/164A) mutations (Figures 6a and b).
In addition, we confirmed that pharmacological inhibition of
GSK3b significantly reduced cell proliferation of PAX3-
FOXO1 expressing cells (Figure 6c). Collectively these
findings strongly indicate that GSK3b activity promotes the
tumorigenicity of RH30 cells and that this effect is neutralized
by expression of MYOGENIN bearing mutations that render it
insensitive to GSK3b.
Electrical stimulation of ARMS-derived RH30 cells
reduces GSK3b activity through Akt (PKB). Electrical
stimulation of skeletal muscle cells in cell culture has been
shown to induce phenotype alterations and differentiation.33
Given that rhabdomyosarcoma shares properties of the
skeletal muscle lineage, we electrically stimulated cultured
RH30 cells for 4 h/day (5 Hz) for up to 4 days with the idea
that it might promote differentiation by affecting the
Akt/GSK3b signaling pathway.34 Stimulation of these cells
resulted in an increase in pAktT308 to levels that were
3.00±0.72-fold higher than those in non-stimulated cells
after 4 days of stimulation (Figures 7a and b). Concomitantly,
pGSKbS9 was also increased 2.25±0.37 fold following 4
days of stimulation (Figures 7a and c). These increases in
pAktT308 and pGSKbS9 were not a result of increases in
total protein (Figure 7a) as indicated by the 3.76±1.32 and
2.05±0.55 increases in relative phosphorylation, respec-
tively (Figures 7d and e). These changes in kinase activity
corresponded with increased E-box promoter activity in
stimulated cells compared with controls (Figure 7f). Collec-
tively, these data indicate that electrical stimulation
suppresses GSK3b activity and correspondingly activates
MRF activity supporting our previous findings and also
highlighting the possibility of using electrical stimulation as
a therapeutic intervention in ARMS patients.
Discussion
ARMS, unlike ERMS, has a well-characterized cytogenetic
basis in the majority of patients resulting from chromosomal
translocations between chromosomes 1 and 13 and also 2
and 13 that result in fusion of the DNA binding domains of
either Pax7 or PAX3 with the trans-activation domain of the
Forkhead (FKHR) transcription factor family member
Foxo1.1,2,35 In view of the well-substantiated crucial role of
PAX3 and 7 in the development of skeletal muscle4,5 it is
therefore not surprising that the signature of ARMS tumor
cells is a muscle-like phenotype and the expression of a
variety of structural muscle marker genes such as myosin
heavy chain and desmin.36 What is surprising is the sustained



















































Figure 5 Pharmacological inhibition of GSK3b rescues PAX3-FOXO1
repression of MYOGENIN’s transcriptional activation of MCK promoter in both
C2C12 myoblasts and RH30 human ARMS cells. (a) MCK-Luc promoter activity
was assessed in C2C12 myoblasts that were transfected with different
combinations of MYOGENIN, PAX3-FOXO1 and pcDNA3.1 control plasmid as
indicated and then treated with either 10mM AR-A014418 or DMSO solvent.
MYOGENIN enhanced MCK-Luc activity as expected (Po0.001) and this effect
was repressed by co-expression of PAX3-FOXO1 (Po0.01). Pharmacological
inhibition of GSK3b not only reversed the effect of PAX3-FOXO1 but resulted in a
super-activation (Po0.001). (b) To assess the importance of these findings in
human-derived ARMS, RH30 cells were transfected with either MYOGENIN or
mutated MYOGENIN(S160/164A) and MCK-Luc promoter activity was assessed.
The data shows that wild-type MYOGENIN could not trans-activate the MCK
promoter region unless it was coupled with pharmacological inhibition of GSK3b
(Po0.001). This was in contrast to mutated MYOGENIN (S160/164A), which could
potentiate MCK promoter activity (Po0.001) regardless of GSK3b inhibition.
(c) Summary of our findings: GSK3b activity in ARMS represses the activation of
muscle-specific genes by repressing the transcriptional activity of MYOGENIN. #ns,
*Po0.01, **Po0.001
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which are transcription factors that are intimately associated
with the terminally differentiated, non- proliferative phenotype
of normal myogenic cells, begging the question as to why they
cannot exert this effect in ARMS. In particular, the function of
MYOGENIN in the myogenic regulatory hierarchy places it at
a pivotal and required step in the terminal commitment of
myogenic progenitors to the differentiation program.19,20,34
Thus, our observations reported here, that MYOGENIN
function in ARMS is repressed by inappropriate sustained
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Figure 6 Soft agarose colony formation and MTT cell proliferation assays: (a) Equal numbers of RH30 cells were seeded under different conditions as depicted, and
allowed to form colonies for 21 days. On the 22nd day the colonies were stained with 0.005% Crystal Violet overnight. Colonies were counted at different planes (n¼ 10) in
four independent experiments done in triplicate. The total number of colonies was reduced by (i) 10mM AR-A014418, Po0.05 (ii) Transient transfection of MYOGENIN
containing the S160/164A neutralizing mutations, Po0.01 and (iii) both, Po0.001. Also see Supplementary Figure 1 for visual representation of the data. (b) We searched for
the three largest colonies in each of the 12 plates for each condition and calculated the area using ImageJ software. The data revealed that the control colonies could grow up
to 9 bigger than any of the experimental conditions, Po0.001. (c) MTT cell proliferation assays were performed in PAX3/FOXO1A-expressing cells with and without 10 mM
AR-A014418 treatment. The experiment revealed that GSK3b inhibition reduces cell proliferation byB2-fold, Po0.001. #ns, *Po0.05, **Po0.01, ***Po0.001
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significance for understanding the etiology of this disease.
Moreover, as repression of kinase activity is, in many cases, a
tractable pharmacologic approach, we now propose targeting
GSK3b activity as a tangible therapeutic strategy for ARMS.
In support of the above, a recent study showed that ARMS-
associated PAX3/7-Foxo1 fusion proteins inhibit MYOD
target genes.39 It was also reported that forced MYOD/E-
protein dimer expression could not rescue PAX3/7-Foxo1
repression of myogenic factors.39 Here, we also report that
ectopically expressed PAX3-FOXO1 represses the induction
of muscle genes, even when MRFs are expressed. We
propose that the posttranslational repression of MYOGENIN
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Figure 7 In vitro electrical stimulation of RH30 cells. (a) Western blot analysis revealed that electrical stimulation increased PKB/Akt activity and that this corresponded with
increased phosphorylation of GSK3b at S9. Relative increase of phosphorylation at: (b) Akt at T308 and (c) GSK3b at S9, over time. Graphical representation of phosphorylated to
total amounts of: (d) Akt and (e) GSK3b. (f) E-box promoter activity decreased with electrical stimulation and this also corresponded with inhibition of GSK3b at S9. *Po0.01,
**Po0.001
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activity is due to sustained GSK3b activity and, through a
cross-talk mechanism, subsequent repression of p38 MAPK
(Supplementary Figure 1) as we have previously described.10
p38 MAPK and PKB/Akt are both required for activation
of MEF2/MYOD transcriptional control and chromatin
remodeling events at crucial myogenic loci for the differentia-
tion program.11,40
In other systems, GSK3b phosphorylation of its protein
substrates results in subsequent targeting for proteasomal
degradation.12,13 However, GSK3b does not appear to affect
MYOGENIN protein stability in our experiments as we
observe an increase in a slow migrating, hyperphosphorylated
form of MYOGENIN in response to GSK3b signaling that is
not reduced in terms of its level of expression suggesting that
proteasomal degradation of MYOGENIN is not enhanced by
GSK3b. Conversely, neutralizing mutations of the GSK3b
consensus enhanced MYOGENIN trans-activation of the
muscle creatine kinase promoter, and also reduced the
tumorigenic properties of ARMS cells (RH30) in a
colony-formation assay. These findings suggest that
GSK3b-mediated inhibition of MYOGENIN trans-activation
properties impairs MYOGENIN’s ability to promote terminal
differentiation in tumorigenic RH30 cells.
Cell cycle control is an essential component of normal
growth control and development which goes awry in
tumorigenesis. To date several growth-promoting PAX3-
FOXO1 target genes have been implicated in RMS such as
the IGF-R and c-Met although, while their contribution to
proliferation is likely, the extent of their precise involvement in
ARMS is still not clear.41 During normal skeletal myogenesis,
upregulation of a cyclin-dependent kinase inhibitor, p21, stalls
myoblasts in the G2/M phase of the cell cycle thus
priming them for differentiation by promoting cell cycle exit,
which is a requirement for subsequent muscle-specific gene
expression.42 Consistent with the idea that GSK3b activation
may contribute to the oncogenic properties resulting from
PAX3-FOXO1 expression in ARMS, we observed that the
number of proliferative RH30 cells is approximately halved by
pharmacological inhibition of GSK3b. So far, the exact
mechanism by which GSK3b regulates cell proliferation in
ARMS is unknown. However, GSK3b has recently been
shown to activate KLF643 and we recently identified
that KLF6 enhances cell proliferation in myogenic
cells through a TGFb/Smad3 dependent pathway.44 We
therefore speculate that PAX3-FOXO1/GSK3b enhance-
ment of cell proliferation may involve KLF6 as a downstream
effector as it is also highly expressed in various RMS
cell types.
In summary, MYOGENIN normally activates genes that
regulate cell fusion and terminal differentiation of skeletal
muscle. In PAX3-FOXO1 expressing ARMS cells, our data
indicate that sustained GSK3b activity represses MYOGENIN
function, contributing to the transformed, proliferative pheno-
type of these cells. On the basis of this evidence, we propose
that pharmacologic targeting of GSK3b kinase activity may
constitute a tractable therapeutic strategy for ARMS.
Materials and Methods
Plasmids. E-box, MYOGENIN and MCK reporter constructs in pGL3 and
expression vectors for MYOGENIN in EMSV were used in reporter gene assays.
HA-tagged PAX3-FOXO1 was cloned into pcDNA3.1 and kindly donated by
Dr. Malkin at MaRS, Toronto. HA-tagged GSK3b(S9A) was cloned in pcDNA3
ORF 995–2305.
Antibodies. Anti-MYOGENIN and anti-HA mouse monoclonal antibodies as
well as anti-MEF2A rabbit polyclonal antibody were produced with the assistance
of the York University Animal Care Facility; anti-PAX3 (1 : 250; Cell Signaling,
Whitby, ON, Canada) GSK3b, phospho-GSK3b (1 : 1000; Cell Signaling);
actin, MYOD, Myf-5, GFP, dsRed2 (1 : 2000; SantaCruz, Santa Cruz, CA, USA)
were used for immunoblotting experiments.
Cell culture and transfection. C2C12, Cos7 and RH30 cells were
maintained in DMEM supplemented with 10% fetal bovine serum (HyClone,
Burlington, ON, Canada), 1% L-glutamine and 1% penicillin-streptomycin. Cells
were maintained in a humidified, 37 1C incubator with a 5% CO2 atmosphere. For
transfections, cells were seeded 1 day before transfection and transfected
according to the standard calcium phosphate method previously described.
A mixture of 50 ml 2.5 M CaCl2 per 25mg DNA with an equal volume of 2x HeBS
(2.8 M NaCl, 15mM Na2HPO4, 50mM HEPES, pH¼ 7.15) was used and the cells
were incubated overnight followed by washing and addition of fresh media. The
cells were counted and transferred to pre-gelatin-coated plates.
Protein extractions, immunoblotting and reporter gene assays.
Cells were collected using an NP-40 lysis buffer (0.5% NP-40, 50mM Tris-HCl
(pH 8.0), 150mM NaCl, 10mM sodium pyrophosphate, 1 mM EDTA (pH 8.0),
0.1 M NaF) containing 10mg/ml leupetin and aprotinin, 5mg/ml pepstatin A,
0.2 mM phenylmethylsulfonyl fluoride and 0.5 mM sodium orthovanadate. Protein
concentrations were determined using the Bradford method (Bio-Rad,
Mississauga, ON, Canada) with bovine serum albumin (BSA) as a standard. An
amount 20mg of total protein extracts were used for immunoblotting, diluted in
sample buffer containing 5% b-mercaptoethanol and boiled.
Transcriptional assays were done using luciferase reporter plasmids. The cells
were collected for these assays using 20mM Tris, (pH 7.4) and 0.1% Triton-X 100
and the values obtained were normalized to b-galactosidase activity expressed from
a constitutive SV40 driven expression vector and represented as relative light units
(RLU) or in some cases corrected Luciferase values for control, reporter alone
transfections were arbitrarily set to 1.0, and fold activation values were calculated.
Bars represent the mean (n¼ 3) and error bars represent the standard error of the
mean (n¼ 3). Independent two sample t-tests of all quantitative data were
conducted using R software. P-values are indicated with respect to controls where
appropriate.
In vitro kinase assay. A total of 3 mg of purified recombinant
GST-MYOGENIN was mixed with either 0.5mg purified recombinant GST-GSK3b
(1–433; Cell Signaling) and with (g-32P) ATP and incubated for 30min at 30 1C.
Samples were denatured for 5 min at 95 1C in SDS sample buffer. Protein samples
were then separated by 10% SDS-PAGE and exposed on X-ray film
(Kodak X-Omat, Toronto, ON, Canada) for 21 h to detect 32P incorporation. The
lanes containing GST-MYOGENIN are elongated because two lanes were pooled
to fit a higher total reaction volume to accommodate for the low concentration of
purified GST-MYOGENIN (0.06mg/ml). All lanes contain equal total amounts of
proteins (3mg).
Electrical stimulation. Cells were plated onto 0.1% gelatin-coated 6-well
plates. The lids of the plates were fitted with two parallel platinum wire electrodes,
placed at the opposite ends of each well and extending into the media. The wires
from all wells were arranged in parallel and connected to an electrical stimulator
(Harvard Apparatus Canada, Saint-Laurent, Quebec, Canada). Cells were
stimulated at 5 V and a frequency of 5 Hz for 4 hours/day and allowed a
subsequent 20 h recovery period. Cells were collected following the recovery
period throughout the 4 days of the protocol.
Soft agarose colony-formation assay. Materials: 0.7% (w/v) DNA
grade Agarose, 1% (w/v) DNA grade Agar, 0.005% Crystal Violet (Sigma-Aldrich,
Oakville, ON, Canada), 2X Mediaþ 20% (v/v) FBS. After 48 h of transfection with
MYOGENIN containing the S160/164A mutations or empty vector, RH30 cells
were assayed for their capacity to form colonies as previously described.45 A total
of 1 104 cells were suspended on a layer of 0.35% agarose in DMEM (10%
FBS) with or without 10 mM AR-A014418, in 6-well plates. Medium was refreshed
every 3–5 days as needed and on the 22nd day, the amount of colonies were
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counted using a contrast phase microscope. The relative colony sizes were
calculated using ImageJ software (Scion Corporation, Frederick, MD, USA). Four
independent experiments were carried out in triplicate.
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